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Summary 
 
Today it is recognized that a variety of enzymes are generating gas mediators, 
molecules that exert important physiological functions. Also, there is a growing body of 
evidence which suggests that methane (CH4) can be produced in the eukaryotic cell. The anti-
inflammatory potential of exogenously supplemented CH4 has been repeatedly confirmed as 
well, but important details of the mechanism of action still need to be clarified. The main 
purpose of the thesis was to summarize and interpret previous data on the in vivo properties of 
exogenous CH4 in order to design and conduct further experiments, which help to extend our 
knowledge on the possible role and mechanisms of action of CH4 in mammalians. 
Therefore, our first general aim was to explore the effects of normoxic CH4 
administration in a small animal model of mesenteric ischemia-reperfusion (IR) induced 
inflammation. The early and later consequences of intestinal IR were characterized by 
mucosal permeability, biochemical, macro- and microcirculatory and morphological 
parameters. The IR-induced circulatory and structural damage was accompanied by increased 
epithelial permeability, demonstrating mucosal barrier damage. An assessment of the kinetics 
of the inhaled CH4 revealed that in our inhalation regime, at the end of ischemia significant 
amounts of CH4 are already in the systemic circulation, allowing rapid equilibration with the 
intestinal tissue early in the reperfusion, as confirmed by photoacoustic spectroscopy 
measurements. Normoxic CH4 inhalation effectively prevented the elevation of intestinal 
epithelial permeability, maintaining structural integrity of the mucosa and improving 
biochemical signs of inflammation in the early reperfusion. These data support previous 
findings on CH4 bioactivity and establish a mucosa-protective role for exogenous CH4 to 
modulate the IR-induced pro-inflammatory activity locally in the small intestine. 
Our second general aim was to delineate the mechanisms of action of CH4 in models 
of tissue hypoxia with elevated levels of reactive oxygen and nitrogen species, with special 
emphasis on the possible relationship of CH4 with other biological gases, such as nitric oxide 
(NO). 
Based on the above results two hypotheses for the mechanism of action were 
formulated and tested. First, we supposed that CH4 is able to directly influence cell membrane 
rigidity. Accordingly, we set out to investigate the influence of CH4 on changes in erythrocyte 
deformability provoked by oxidative stress in vitro. The results revealed that CH4 in vitro 
improves the deformability of red blood cells during simulated oxidative stress, which may 
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contribute to the improvement of the effectiveness of mesenteric microcirculation in the 
postischemic small intestine. 
The second hypothesis of action of exogenous CH4 was a direct interaction with NO 
metabolism. A new, non-toxic, exogenous spin trap-free electron paramagnetic resonance 
(EPR) spectroscopy method was developed for NO detection. The method was validated in a 
bacterial endotoxin-based in vivo experimental model of inflammation where NO 
concentration was measured from both the intra- and extracellular compartments of the same 
samples in tissue biopsies. With EPR spectroscopy reduced NO levels were detected in the 
ischemic intestinal tissue after normoxic CH4 administration. Considering this information, we 
set out to measure NO release in real-time in vitro from liver tissue homogenate under anoxic 
conditions, mimicking ischemic tissue. CH4 treatment under such conditions inhibited NO 
release. Collectively, these results confirm that exogenous CH4 administration effectively 
reduces NO levels in the ischemic tissue. 
In conclusion, our data demonstrates an anti-inflammatory and mucosa-protecting role 
of CH4 in intestinal IR. To shed light on the mechanism of action, we confirmed direct effects 
of CH4 on oxidized erythrocyte membranes and that increased CH4 input reduces NO 
production and nitrotyrosine levels in hypoxic and anoxic organs. 
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Összefoglalás 
 
Napjainkra számos enzimről bizonyosodott be, hogy gáznemű jelátvivő molekulák 
termelésére képesek. Ezen mediátorok fontos élettani funkciókat szabályoznak. Egyre több 
bizonyíték szól amellett, hogy eukarióta sejtekben metán (CH4) képződhet. A kívülről 
bejuttatott CH4 gyulladásgátló hatását is többször megerősítették, azonban a 
hatásmechanizmus fontos részletei még tisztázatlanok. E dolgozat fő célja az exogén CH4 in 
vivo hatásairól rendelkezésre álló adatok összegzése és értelmezése, majd további kísérletek 
tervezése és kivitelezése volt, melyek gyarapíthatják tudásunkat a CH4 emlősökben betöltött 
szerepéről. 
Első fő célunk a normoxiás CH4 bevitel hatásainak és következményeinek vizsgálata 
volt mesenteriális ischaemia-reperfúzió (IR) által okozott gyulladásos reakció alatt. A 
vékonybél IR korai és késői következményeit a nyálkahártya permeabilitás meghatározásával, 
biokémiai, makro- és mikrohaemodinamikai valamint morfológiai vizsgálatokkal jellemeztük. 
A vékonybél IR mikrokeringési és strukturális károsodása megemelkedett epitheliális 
permeabilitással járt, jelezve a mucosa barrier károsodását.  A belélegzett CH4 időbeli szöveti 
eloszlásának fotoakusztikus spektroszkópos vizsgálata feltárta, hogy az általunk alkalmazott 
lélegeztetési módszerrel már az ischaemia végén jelentős mennyiségű CH4 van a szisztémás 
keringésben, mely a bélben a koncentráció gyors kiegyenlítődését teszi lehetővé a reperfúzió 
elején. Normoxiás CH4 belélegzése hatékonyan gátolta a vékonybél epitheliális permeabilitás 
növekedését, megőrizte a mucosa strukturális épségét és mérsékelte a gyulladás biokémiai 
jeleit a korai reperfúzió során. Az adatok megerősítik a CH4 bioaktivitását bizonyító adatokat 
és megalapozzák az exogén CH4 gyulladáscsökkentő, nyálkahártya-védő hatását IR alatt. 
Másik fő célunk a CH4 hatásmechanizmusának további feltárása volt szöveti 
hypoxiával, valamint fokozott reaktív oxigén és nitrogén származék képződéssel jellemzett 
modellekben. Ennek során a CH4 egyéb gázokkal, pl. nitrogén-monoxiddal (NO) való 
kölcsönhatásaira fektettünk külön hangsúlyt. 
A fenti eredmények alapján két elméletet dolgoztuk ki és vizsgáltuk meg. Elsőként azt 
feltételeztük, hogy a CH4 közvetlenül képes a sejtmembrán-rigiditás befolyásolására. Ehhez 
megvizsgáltuk a CH4 in vitro hatását az oxidatív stressz által kiváltott vörösvérsejt 
deformabilitás változásokra. Eredményeink szerint in vitro szimulált oxidatív stressz alatt a 
CH4 javítja a vörösvérsejtek deformabilitását, mely ezáltal hozzájárulhat a mesenteriális 
mikrokeringés hatékonyságának javulásához ischaemiát követően.  
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A második elmélet szerint az exogén CH4 közvetlenül képes befolyásolni a NO 
metabolizmust. Egy új, nem toxikus, exogén spincsapda-mentes, elektron paramágneses 
rezonancia (EPR) spektroszkópos módszert dolgoztunk ki a NO mérésére. A módszert 
validáltuk egy bakteriális endotoxin-alapú gyulladás állatmodelljében ugyanazon 
szövetbiopsziából történő intra- és extracelluláris NO meghatározásra is. EPR 
spektroszkópiával csökkent NO szintet mutattunk ki vékonybél szövetben in vivo normoxiás 
CH4 kezelés után. Ezen eredményeket megfontolva további vizsgálatokat végeztünk a NO 
felszabadulás valós idejű mérésére máj szövet homogenizátumból, anoxiás körülmények 
között, ischaemiás szövetet utánozva. A CH4 kezelés ezen körülmények között gátolta a NO 
felszabadulást.  Összességében ezen eredmények igazolják, hogy exogén CH4 alkalmazása 
csökkenti az ischaemiás szövet NO szintjét. 
Összefoglalva, adataink a CH4 gyulladásgátló és nyálkahártya védő hatását bizonyítják 
vékonybél IR során. Hogy fényt derítsünk a hatásmechanizmusra, kimutattuk, hogy a CH4 
közvetlenül befolyásolja az oxidált vörösvérsejt membránt és hogy megnövekedett CH4 
bevitel csökkenti az anoxiás és hypoxiás szövetek NO termelését és a nitrotirozin szintet. 
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I. Introduction 
1. Oxygen and aerobic life 
In most vertebrate tissues the majority of oxygen (O2) is consumed by mitochondria, 
the powerhouses of cells. During the aerobic metabolism ATP is produced by protein 
complexes of the electron transport system (ETS) embedded in the inner mitochondrial 
membrane (IMM). In the last cascade step of the electron transfer fed by the metabolites of 
the citrate cycle, the final electron acceptor O2 is reduced at the cytochrome c oxidase (EC 
1.3.3.1) producing H2O:  
 
             M
              
        
          
 (cyt c: cytochrome c, H
+
M:  matrix H
+
, H
+
C: intermembrane H
+
.) 
 
This process contributes to more than 90% of the total O2 consumption of the human 
body. In addition, over 60 enzymes are consumers of the cellular O2, including oxidases (e.g. 
xanthine oxidase (EC 1.17.3.2), aldehyde oxidase (EC 1.2.3.1), amine oxidases, NADPH 
oxidases), and mono- and dioxygenases (e.g. lipoxygenases of the arachidonic acid cascade, 
cytochrome p450 monooxygenase, etc.) (Vanderkooi et al., 1991). Interestingly, in contrast to 
most cell types, not mitochondria, but phagocytic NADPH oxidase is the major sink of O2 in 
activated polymorhonuclear (PMN) leukocytes during the “respiratory burst” since these cells 
generally rely on glycolysis (Segal et al., 1978). 
1.1. Oxygen physiology, normoxia 
Normoxia generally refers to 20-21% O2 in the atmosphere. Within the human body 
the O2 gradient gradually decreases in the respiratory system and across the cells, reaching its 
lowest value in the vicinity of mitochondria. The partial pressure of O2 (pO2) in the lung 
alveoli is 100-110 mmHg (approx. 13 kPa), 90–110 mmHg (12.0–14.7 kPa) in the arterial 
blood, well above the normal extracellular pO2 levels in solid organs (40 mmHg in the 
neocortex and 10 mmHg in the luminal parts of the colon) (Erecinska et al., 2001; Gnaiger, 
2003). Nevertheless, the partitioning factor of O2 is roughly 3, thus local concentrations of O2 
in cellular and mitochondrial membrane fractions are enhanced (Subczynski et al., 1983). 
Here, it should be mentioned that the O2 level in cell cultures is usually much higher 
than in vivo, because in the majority of studies they are incubated at air oxygen pressure. In 
this case the O2 concentration is reaches approximately 200 μM (160 mmHg) in the 
incubation medium at 37°C and ambient pressure, representing relative hyperoxia compared 
to the in vivo situations (Gnaiger, 2003; van Faassen et al., 2009). 
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1.2. The mitochondrial ETS and O2 
Mitochondria are spatially separated intracellular sites hosting a series of oxido-
reductive reactions coupled to proton pumping. The initial shuttle carrier of electrons from the 
citric acid cycle to the membrane-bound respiratory chain of flavoproteins is the 
NAD
+
/NADH couple. Complex I (CI, NADH:ubiquinone oxidoreductase, EC 1.6.5.3) feeds 
electrons in the ubiquinone pool located in the IMM. Subsequently, electrons are carried by 
Complex III (CIII, cytochrome c reductase, EC 1.10.2.2) to cytochrome c and then to 
Complex IV (CIV, cytochrome c oxidase, EC 1.9.3.1), where O2, the final electron acceptor, 
is reduced. The other main way of electrons converging at the ubiquinone pool is driven by 
Complex II (CII, succinate dehydrogenase, EC 1.3.5.1), the only membrane-bound enzyme of 
the citrate cycle. According to the chemiosmotic coupling hypothesis of Mitchell (1961), 
protons are pumped with the energy of oxidation-reduction at the CI, CIII and CIV across the 
IMM to the intermembrane space, which is the driving force of the ATP synthesis by the F0-
F1 ATPase (Mitchell, 2011). 
1.3. Sources and sinks of mitochondrial reactive oxygen species (ROS) 
According to Vladimir Skulachev “living with the risk of oxidative stress is a price 
that aerobic organisms must pay for more efficient bioenergetics” (Skulachev, 1996). During 
the electron transfer over the ETS 1-4% of electrons “leak”, producing partially reduced 
superoxide (O2
●−
), the primary reactive oxygen species (ROS) in the eukaryotic cell (Chance 
et al., 1961). There are at least 10 known enzymes in mammalian mitochondria which are 
able to produce ROS, some of them at several sites within the same protein complexes (i.e. 
CI, CII and CIII), these also include the cytochrome b5 reductase, monoamine oxidases A and 
B, dihydroorotate dehydrogenase, glycerol-3-phosphate dehydrogenase, aconitase, and the α-
ketoglutarate dehydrogenase complex (Andreyev et al., 2005; Quinlan et al., 2012). However, 
most of the experiments that indicate net ROS production of these organelles were done on 
isolated mitochondria or on submitochondrial particles, usually by means of detection 
methods, which are based on trapping reactive species by molecules that have a high affinity 
to ROS, generating detectable adducts upon reaction. Optical and electron spin resonance 
spectroscopic techniques are commonly used to detect such adducts.  
The rate of ROS production strongly depends on the metabolic state of the cells and 
the contribution of mitochondria to the cellular ROS pool is still debated (Hansford et al., 
1997; Tahara et al., 2009). It has been suggested that in situ, under physiological conditions, 
mitochondria might be more like sinks than sources of ROS, if the high antioxidative capacity 
of mitochondria is taken into account (Brown et al., 2012). The mitochondrial ROS-
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detoxifying mechanisms among others include the membrane lipid peroxide removal systems, 
phospholipid hydroperoxide glutathione peroxidase, manganese superoxide dismutase, 
cytochrome c, catalase, glutathione, glutathione-S-transferase, glutathione reductase, 
glutathione peroxidase and peroxiredoxins. This suggests that ROS production is tightly 
regulated and secured by several lines of antioxidant defense systems in intra- and extra-
mitochondrial sites. Today it is commonly accepted that physiological levels of ROS regulate 
a variety of signaling pathways (e.g. NF-κB, Nrf-2, STAT3) directly and indirectly 
(Hamanaka et al., 2010; Niture et al., 2014; Weidinger et al., 2015). 
 
2. Hypoxia and reoxygenation, ischemia and reperfusion, pathological ROS generation 
2.1. Hypoxia and ischemia 
The impairment of arterial blood flow leads to tissue hypoxia, with lower-than-
physiological levels of O2; the exact value will depend on the energetic needs of the tissue 
which is already rate-limiting for mitochondrial oxidative phosphorylation (OXPHOS). 
Taking into account the fact that the KM value of cytochrome c oxidase is well below 1 µM 
for O2 in uncoupled mitochondria, local hypoxia usually means O2 levels below 2 µM. 
However, the KM value is between 1-10 µM in states with a high proton motive force and a 
small difference in redox potential across the ETS (Petersen et al., 1974; Krab et al., 2011). 
Furthermore, KM values for O2 of the most important O2-utilizing enzymes strongly depend 
on the presence of other substrates and gaseous compounds, such as nitric oxide (NO) and 
carbon monoxide (CO) (Thomas et al., 2001; Cooper et al., 2008). 
The dysfunction of mitochondria is central to hypoxic tissue injuries. Several aspects 
of this condition have already been explored, such as impaired ATP production, an increase in 
ATP hydrolysis to maintain the mitochondrial membrane potential (Δψm), dysregulated 
mitochondrial Ca
2+
 homeostasis and elevated ROS production (Di Lisa et al., 2006). 
Mitochondrial permeability transition is a process leading to the assembly and opening of a 
voltage-dependent, high conductance channel in the IMM. In pathological conditions, the 
sustained opening of mPTP can lead to irreversible mitochondrial damage and apoptosis. ROS 
and Ca
2+ 
are known triggers of pore opening. Upon permeability transition, Δψm collapses and 
ATP synthesis ceases. In a self-protecting endeavor of mitochondria to maintain Δψm, the 
cytosolic ATP from glycolysis is hydrolyzed by reversed ATP synthase, further depleting the 
energy sources of the cell. As a secondary process, the outer mitochondrial membrane 
(OMM) disrupts and cytochrome c will be released in the cytoplasm, inducing apoptosis 
(Bernardi et al., 2015). 
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2.2. Reperfusion injury 
The mitochondrial and non-mitochondrial pathophysiology of ischemia-reperfusion 
(IR) injury is a rather well-explored topic in biomedical research (Granger et al., 2015). In the 
absence of O2, which is the final electron acceptor of the respiratory chain, the cascade of 
redox reactions stops and reducing equivalents accumulate. Generally speaking, the duration 
of ischemia determines the survival of the affected tissue and the timely restoration of 
nutritive blood flow is essential to recover organ function. Reperfusion, however, 
paradoxically worsens the initial damage done by the ischemia itself. This is mainly due to the 
reintroduction of molecular O2 to previously ischemic tissue (originally proposed by Hearse 
(Hearse et al., 1973)). The decisive role of ROS formation, or more precisely, an imbalance 
between ROS production and detoxification was later demonstrated by Neil Granger (Granger 
et al., 1981). During hypoxia elevated mitochondrial ROS (mtROS) production occurs, 
mainly due to partial inhibition of respiratory chain enzymes (Kozlov et al., 1999), but this is 
much less than ROS produced upon reperfusion (Parks et al., 1986a). 
An important contributing factor to elevated mtROS production upon reperfusion is 
succinate accumulation during ischemia (Chouchani et al., 2014). Previously, mtROS 
production had been considered a nonspecific process after the re-establishment of O2. The 
research team led by Murphy has shown that succinate is rapidly metabolized during the first 
minutes of reperfusion with concomitant increases of mtROS production by reverse electron 
transport at CI (Zweier et al., 1987; Murphy et al., 2008). In fact, the application of rotenone, 
an inhibitor of CI ameliorates the IR-induced mucosal damage in rodents (Ichikawa et al., 
2004). 
In addition to elevated mtROS production, pathological ROS production in the 
reperfusion period is fueled by cytosolic or extracellular sources. The most important ROS 
source in the postischemic tissue is probably xanthine oxidoreductase (XOR) (Harrison, 2002; 
Khambata et al., 2015). XOR is a complex molybdo-flavoenzyme, originally described by 
Schardinger in 1902 (Schardinger, 1902; Harrison, 2002). It exists as a homodimer of a single 
monomer with 150 kDa MW (Andrews et al., 1964). Each monomer has a FAD domain, two 
iron-sulfur domains and a molybdopterin (Mo) binding site (Khambata et al., 2015). The 
latter is the site of purine catabolism and NO2
−
 reduction, which is an important feature of the 
enzyme. 
XOR is ubiquitous in mammals, being generally recognized as the terminal enzyme of 
purine catabolism, oxidizing hypoxanthine to xanthine and xanthine to uric acid (Harrison, 
2002). XOR has two states, which are interconvertible. Xanthine dehydrogenase (XDH) is the 
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predominant form under physiologic conditions and normoxia. XDH can be converted to 
xanthine oxidase (XO) by reversible sulfhydryl oxidation or by limited proteolysis. The latter 
process is irreversible and occurs during tissue hypoxia at high levels of intracellular Ca
2+ 
(Granger et al., 1986a). Both forms metabolize hypoxanthine, but XO produces O2
●−
, which 
in turn forms H2O2. During ischemia hypoxanthine accumulates, hence XO contributes 
substantially to O2
●−
 induced tissue injury during reperfusion. In 1986, Granger proposed that 
XOR is the major source of O2
●−
 during IR (Granger et al., 1986b) and although concerns 
have been raised over the time (Moorhouse et al., 1987), this model of postischemic O2
●−
 
generation is still widely accepted. Moreover, as has been recently shown, extracellular 
superoxide produced by XOR bound to GAGs on the endothelial surface of capillaries is a 
potent activator of PMNs through Toll-like receptor-4 (TLR4) (Lorne et al., 2008). 
The highest levels of XOR in rodents and humans have been found in the liver and in 
the intestine (Parks et al., 1986b). Interestingly, Harrison and colleagues (Harrison, 2002) 
reported strongly positive anti-XOR antibody staining on the surface of human intestinal 
epithelial cells, and the enzyme was detected in the TJs of cultured intestinal epithelial cells as 
well. 
 
3. Hypoxia and inflammation 
Hypoxic conditions are inducing inflammation, and inflammatory disease states are 
frequently accompanied by tissue hypoxia. IR injury is also characterized by an inflammatory 
response and an important contributing factor to the oxidative tissue damage is the activation 
of the innate immune system. Extravasated leukocytes produce large quantities of O2
●−
 by 
phagocytic NADPH oxidase and this mechanism can damage host cells and it also reduces 
tissue oxygenation by consuming O2 (Hernandez et al., 1987; Yang et al., 2009).  
Activated PMNs are not only important contributors to the oxidative stress, but also 
play a significant role in microcirculatory derangements. The massive expression of adhesion 
receptors induces leukocyte rolling and firm adherence to postcapillary endothelial cells, 
which leads to elevated flow resistance, endothelial dysfunction and tissue edema (Menger et 
al., 1997; Szabo et al., 2008). 
An important feature of reperfusion injury is the no-reflow phenomenon. The 
maintenance of normal red blood cell deformability is a prerequisite of intact 
microcirculation, since only bullet-shaped erythrocytes can pass capillaries freely. The 
peroxidation of membrane lipids of RBCs by oxidant species, such as peroxynitrite (ONOO), 
decreases the fluidity of the affected cellular membranes, contributing to reduced capillary 
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blood flow (Dobretsov et al., 1977) and in severe cases, capillary stasis can develop (Vollmar 
et al., 2011). Notably, the direct effects of NO on membrane rigidity were shown earlier 
(Tsuda et al., 2000) and the adsorption of non-polar molecules in lipid bilayers was 
demonstrated in model experiments (Gruen et al., 1980). 
3.1. Inflammatory mediators 
The umbrella term “inflammatory mediator” covers molecules and cells contributing 
to the initiation, propagation and controlled cessation of the inflammation cascade. Most of 
them are “soluble” compounds such as cytokines, small protein products of immune cells or 
other cell types. The most prominent players in acute inflammation are tumor necrosis factor 
α (TNF-α), interleukins (ILs), lipid mediators (e.g. leukotrienes), and the members of the 
complement cascade. However, the role of damage-associated molecular patterns (circulating 
mitochondrial DNA, HMGB-1, hyaluronan fragments, etc.) is increasingly recognized in 
sterile inflammation (Piccinini et al., 2010; Goodall et al., 2014; Maeda et al., 2014). 
ROS (predominantly H2O2) are also local inflammatory signal transducer molecules. 
Gaseous compounds, such as NO, CO and H2S represent a special class of inflammatory 
mediators (Liu et al., 2012). From this perspective, the contribution of the inflammatory cells 
of the monocyte-macrophage axis is of especial importance in gas signal generation and the 
bulk release of cytokines as well (MacMicking et al., 1997). 
Endothelin-1 (ET-1) and interactions with NO 
The regulation of the microcirculation is accomplished by a continuous interaction of 
vasoconstrictor and vasodilator forces. NO and ET-1 are natural counterparts in this complex 
mechanism. ET-1, a pro-inflammatory compound, is the most potent vasoconstrictor agent 
that predominantly acts on ETA receptors, a subtype expressed mainly by vascular smooth 
muscle cells mediating vasoconstrictor effects. ETB receptors on endothelial cells mediate 
mixed effects (Masaki, 2004; Schneider et al., 2007). It has been shown that even low 
concentrations of NO can effectively inhibit ET-1 release and ET-1-linked functions (Bourque 
et al., 2011). Shear stress induces NO production by eNOS, and NO, in turn, inhibits ET-1 
release from cells (Kuchan et al., 1993). Multiple pathways of inhibition have been shown, 
but the most relevant under acute conditions is the inhibition of ETA-phospholipase C 
mediated intracellular Ca
2+
-release by NO (Goligorsky et al., 1994; Bourque et al., 2011). 
Reduced NO production during IR can leave ET-1-mediated vasoconstriction unopposed, 
leading to increased vascular tone and reduced microvasular blood flow, eventually 
exacerbating the IR injury (Martinez-Revelles et al., 2012). Importantly, increased levels of 
plasma ET-1 after intestinal IR were previously reported (Kurtel et al., 1999; Guzman-de la 
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Garza et al., 2009) and ET-1 receptor blockers can alleviate mesenteric IR injury (Oktar et al., 
2002).  
3.2. Intestinal IR injury 
The mucosa forms a physical defense barrier between the intestinal lumen and the 
body, thus any factor which jeopardizes this defense is of vital concern. Occlusive or non-
occlusive mesenteric ischemia with subsequent reperfusion has a common consequence, 
which results in oxidative injury to the mucosa. The causes are energy imbalance, the 
activation of inflammatory pathways and uncontrolled interactions between ROS and reactive 
nitrogen species (RNS) resulting in damage to membrane lipids, proteins and DNA. This can 
cause an irreversible structural damage to biological membranes impairing their permeability 
and facilitating the leakage of toxins and bacteria from the intestinal lumen to the blood.  
Being a component of the cell wall of Gram-negative bacteria, which are known to 
occur in abundance  in the intestine, bacterial lipopolysaccharide (LPS, endotoxin) is thought 
to play an important role in the development of systemic inflammation, sepsis and multiple 
organ dysfunction syndrome originating from the gut after low flow states and IR conditions 
(Olofsson et al., 1985). The increased mucosal permeability of the intestine permits the 
translocation of LPS and even bacteria, initiating a TLR4-NF-κB mediated acute 
inflammation. The translocation of LPS leads to the priming of PMNs (Deitch et al., 1994; 
Moore et al., 1994) as well and the production of inflammatory cytokines, which, in turn, 
exacerbate systemic inflammation. 
However, circulating LPS is only the tip of the iceberg, while the majority of LPS is 
attached to thrombocytes, erythrocytes and TLR4 on immune cells and parenchymal cells 
inducing variety of pathologic signaling cascades in those cells (Cavaillon et al., 2006). 
The inflammatory response provoked by bacterial endotoxin in model systems is dose 
dependent. The LPS-linked reactions are mediated by TLRs and as part of the cellular stress 
response, the generation of both O2
●−
 and NO is one of the major consequences of LPS 
exposure in various TLR4-expressing cell types, including macrophages, PMNs and 
endothelial cells (Mittal et al., 2014; Vaure et al., 2014). This, in turn, makes LPS a useful in 
vivo and in vitro tool for studying the activation of mammalian immune system and the 
production of inflammatory mediators. Since the majority of mechanistic studies on basic 
inflammatory reactions have been conducted in LPS models, a huge body of literature has 
accumulated and the exploration of novel reactions and pathways is easier under such well 
standardized circumstances. 
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3.3. The intestinal atmosphere and the epithelial barrier 
The gastrointestinal (GI) mucosal barrier is one of the most important frontiers of the 
body with an average area of 32 m
2
 in adults (Helander et al., 2014), a large interface between 
the milieu interieur and the surrounding luminal compounds. Although the composition of the 
Earth's atmosphere is relatively well known, but only incomplete datasets are available on the 
gas composition of the mammalian GI tract. In 1971, the survey of Levitt and colleagues 
reported on the gas composition of healthy human volunteers (Levitt, 1971), very low O2 
levels (O2: 0.69±0.49%) were found, and the average for N2 was 64±21%, for CO2: 14±7%, 
for H2: 19±16% and for CH4 levels ranging up to 20% in the producers. Much more data 
should be collected on this important subject, if we consider the dependency of biochemical 
processes on substrate concentrations. Nevertheless, it is well known that the small intestines 
and the colon have unique oxygenation profiles (Glover et al., 2016) and a number of 
mechanisms have been developed by intestinal cells to cope with this biochemical 
environment. The gut mucosa is metabolically very active, but O2 levels are rather low in the 
lumen of the bowel, reaching practically zero in the colon (Levitt, 1971; Glover et al., 2016) 
The O2 demand is highest and hypoxia tolerance is the lowest at the apical region of the villi 
(Vollmar et al., 2011), and the countercurrent circulatory exchanger system along the villus 
axis also contributes to the development of significant intestinal hypoxia, especially in low-
flow states (Åhrén et al., 1973; Haglund et al., 1975). 
In spite of the relatively poor O2 supply, the epithelial cells should sustain several 
processes with high energy demand, including, firstly, the selective absorption of nutrients. 
To cope with energy needs, epithelial cells are able to oxidize significant amounts of 
metabolites transported from the apical side, such as short-chain fatty acids and amino-acids 
(Blachier et al., 2009; Blouin et al., 2011). 
Secondly, to maintain the function of the inter-epithelial tight junctions (TJs) and 
adherent junctions (AJs) of the selectively permeable mucosal barrier (Laukoetter et al., 2006; 
Citalan-Madrid et al., 2013; Glover et al., 2016), a continuous energy supply is needed. It has 
been shown in vitro that ATP depletion leads to the dissolution of TJs and AJs, but existing 
junctional complexes can be “reused” if ATP levels are restored within a short period of time. 
(Tsukamoto et al., 1997; Bush et al., 2000). Similar results were obtained in vivo. It has been 
shown that mesenteric ischemia and reduced mucosal ATP levels lead to TJ dysfunction and 
elevated permeability (Salzman et al., 1995; Wattanasirichaigoon et al., 1999). Cytosolic 
creatine kinase (CK) plays an important role that covers intermittent phases of high energy 
demand, with the help of the cellular phosphocreatine pool, the CK-catalyzed ATP/ADP 
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conversion acts as a buffer of cytocolsic phosphorylation potential (Glover et al., 2013; 
Kitzenberg et al., 2016). 
Interestingly but not surprisingly, “physiological hypoxia” is critical for the expression 
of innate immune factors and TJ proteins (Kelly et al., 2013; Saeedi et al., 2015). At low O2 
levels HIF-1α is stabilized, leading to the gene expression of proteins critically involved in the 
effective barrier function (Colgan et al., 2015).  
During inflammation the intestinal tissue can become profoundly hypoxic, or even 
anoxic despite the non-vascular origin of the disease. Contributing factors are edema, 
increased O2 expenditure and decreased O2 delivery to the inflamed mucosa, aggravated by 
the NADPH-oxidase dependent O2 consumption of extravasated PMNs (Campbell et al., 
2014). 
 
4. Biologically active gases 
While the term “gasotransmitter” does not completely cover “biologically active 
gases”, there is a significant overlap between the groups. Gasotransmitters are defined by four 
characteristics (simplicity, availability, volatility and effectiveness, respectively), and six 
additional criteria were recently listed by Wang (Wang, 2014). Accordingly, gasotransmitters 
are (1) small molecules of gas; (2) freely permeable to membranes; (3) endogenously 
generated in mammalian cells with specific substrates and enzymes; (4) have well-defined 
specific functions at physiologically relevant concentrations; (5) the functions can be 
mimicked by their exogenously applied counterparts; and (6) have specific cellular and 
molecular targets. Today the most well-known gasotransmitter compounds are NO, H2S and 
CO (Wang, 2014). 
4.1. Nitric oxide (NO) 
Furchgott and Zawadzki proposed the existence of an endothelium-derived 
vasorelaxing factor (EDRF) in 1980 (Furchgott et al., 1980), which was later identified as NO 
(Ignarro et al., 1987; Furchgott, 1988). Apart from vasodilation it has several physiological 
functions in cellular signaling, the inhibition of platelet aggregation and leukocyte adhesion 
(Hirst et al., 2011). Under normoxic conditions, NO is mainly produced by various NO 
synthase isoforms (iNOS, nNOS, eNOS) and the majority of the physiological effects are 
based on the activation of soluble guanylate cyclase (sGC) by binding to its heme moiety, 
resulting in increased cGMP levels (Toledo et al., 2012). 
NO possesses an unpaired electron and is therefore regarded as a free radical. 
However, it is relatively stable, reacting only with other free radicals or metals and not 
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forming dimers spontaneously. Its biological life-time varies (approximately 2s under most 
conditions), which is extremely short for a signaling molecule but long as a free radical (most 
of the free radicals have a half-life of milliseconds). Being uncharged, NO readily crosses free 
biological membranes with passive diffusion in all directions. NO is more soluble in 
hydrophobic environments (by a factor of 10), which is an important determinant of its action 
(Thomas, 2015). 
4.2. Carbon monoxide (CO) 
CO is a small molecule (MW 28), non-polar gas messenger. Unlike NO, CO has no 
unpaired electron. Both molecules can bind to the same targets, forming complexes with 
hemoproteins and metalloenzymes. CO is produced endogenously in small quantities by a 
group of enzymes called heme oxigenases (Wu et al., 2005). The therapeutic application of 
CO has been demonstrated in various disease models (Ryter et al., 2006) and CO was 
successfully used in experimental transplantation to minimize IR injury as well (Ozaki et al., 
2012). 
4.3. Hydrogen sulfide (H2S) 
H2S has a structural similarity to H2O. It is membrane-permeable and it can be formed 
both non-enzymatically and enzymatically in bacteria and mammals as well. Similar to CH4, 
sulfate-reducing bacteria in the human intestine are one major source of H2S. It is one of the 
most versatile biologically active gases, influencing an exceptionally wide range of 
physiological and parthophysiological processes (e.g. vascular tonus, myocardial contractility, 
mitochondrial OXPHOS, IR injury) (Wang, 2012). 
4.4. Methane (CH4) 
CH4 is the most reduced form of carbon, the smallest organic compound and the 
simplest alkane. It is odorless, colorless and occurs abundantly in the atmosphere. Because of 
its non-polar properties, the solubility of CH4 is two orders of magnitude higher in membrane 
lipids than in the aqueous phase (Miller et al., 1977; Meyer et al., 1980). CH4 is not toxic per 
se, but a simple asphyxiant, which means that by displacing O2 in closed spaces hypoxia can 
develop. It should be stressed that, in physiologically relevant concentrations CH4 has no 
toxic effects, unless O2 delivery is heavily compromised. Under ambient conditions CH4 is 
accepted to be not reactive, but in the troposphere CH4 is oxidized to CO2 by hydroxyl 
radicals (formed by the photoreaction of tropospheric ozone and water vapor) (Cantrell et al., 
1990; Hurkuck et al., 2012). 
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4.4.1. Bacterial and non-bacterial origin of CH4 in mammals 
In the GI system of most mammals, especially in ruminants, large amounts of 
carbohydrates are fermented. CO2 released during this process is subsequently reduced to CH4 
by the obligate anaerobe prokaryotes, the methanogenic Archaea (Conrad et al., 1999). The 
rate-limiting last step of CO2 oxidation is catalyzed by methyl coenzyme M reductase (EC 
2.8.4.1) (Wongnate et al., 2015). The gas produced is then excreted with the flatus, leaves 
through the skin or can be measured in roughly one third of humans in the exhaled breath 
(Nose et al., 2005; de Lacy Costello et al., 2013). 
The non-microbial formation of CH4 in eukaryotic mitochondria was first 
demonstrated in vitro in 2003 (Ghyczy et al., 2003). It was later shown that during oxido-
reductive stress conditions in animal and plant cell cultures and also in vivo, measurable 
quantities of CH4 are formed (Ghyczy et al., 2008; Wishkerman et al., 2011; Keppler et al., 
2016). Possible ways of in vivo (bio)chemical reactions that are able to produce CH4 were 
reviewed recently (Boros et al., 2015). 
4.4.2. Biological effects 
Much attention has recently been paid to the bioactivity of CH4 in eukaryotes and to 
its possible therapeutic projections. The biological effect of CH4 in the mammalian organism 
was first shown by Pimentel and colleagues (Pimentel et al., 2006). They reported that CH4 
slows the small intestinal propulsive motility and augments contractile activity, thereby 
influencing the enteral nervous/smooth muscle system. Correlations of detectable CH4 in the 
exhaled air of humans and peristalsis changes during irritable bowel syndrome have been 
repeatedly shown as well (Lee et al., 2013; Pozuelo et al., 2015).  
An anti-inflammatory potential for CH4 was first reported by Boros and colleagues in 
experimental mesenteric IR (Boros et al., 2012). Over the past few years many other papers 
have been published on the anti-inflammatory effects of CH4 in various animal models of IR, 
hypoxia and sterile inflammation (see Table 2). Most publications addressed four aspects of 
CH4 activity, namely (1) the modulation of pro-inflammatory cytokine release (TNF-α, IFN-, 
IL-6 and IL-1b); (2) anti-apoptotic effects evidenced by the reduced number of apoptotic 
cells, normalized caspase-3 and caspase-9 activity, decreased Bax and increased Bcl-2 levels 
and/or gene expression; (3) the suppressed generation of oxidative stress biomarkers 
(malondialdehyde, 8-oxo-2'-deoxyguanosine, 4-hydroxynonenal) with concurrent potentiating 
of endogenous antioxidant systems (superoxide dismutase, catalase, glutathione peroxidase); 
and (4) improved organ functions. The key publications on the subject are summarized below 
(Table 1).  
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Topics Source Main findings 
IR injury of skin Song K et al. 2015 BMC Surgery 
CH4-rich saline attenuates the IR injury of 
abdominal skin flaps in rats  
Diabetic retinopathy Wu J et al. 2015 BBRC 
Protective effects of CH4-rich saline on retinopathy 
in a streptozotocin-induced diabetic rat model 
Liver IR injury Ye Z et al. 2015 Shock 
CH4 attenuates hepatic IR injury in rats through 
antiapoptotic and antioxidative actions 
Liver IR injury Strifler et al. 2016 PLOS One 
Inhaled CH4 limits the mitochondrial electron 
transport chain dysfunction during experimental 
liver IR injury 
Myocardial IR 
injury 
Chen O et al. 2016 FRBM 
CH4 attenuates myocardial ischemia injury in rats 
through anti-oxidative, anti-apoptotic and anti-
inflammatory actions 
Concanavalin A-
induced hepatitis 
He R et al. 2016 BBRC 
CH4-rich saline protects against concanavalin A-
induced autoimmune hepatitis in mice through anti-
inflammatory and anti-oxidative pathways 
Exhaustive exercise Xin L et al. 2016 PLOS One 
CH4-rich saline influences stress induced by one-
time exhaustive exercise in rats 
Neuroprotection in 
acute CO poisoning 
Fan D et al. 2016 Brain Res 
Neuroprotective effects of exogenous CH4 in a rat 
model of acute carbon monoxide poisoning 
Retinal IR injury Liu L et al. 2016 Brain Res 
CH4 attenuates retinal IR injury via anti-oxidative 
and anti-apoptotic pathways 
LPS-induced 
immune response 
Zhang X et al. 2016 Sci Rep 
CH4 limits LPS-induced NF-κB/MAPKs signal in 
macrophages and suppresses immune response in 
mice by enhancing PI3K/AKT/GSK-3β-mediated 
IL-10 expression 
Acute CO toxicity Shen M et al. 2016 J Neurol Sci 
Neuroprotective effects of CH4-rich saline on 
experimental acute CO toxicity 
 
Table 1. Recent publications on CH4 bioactivity 
 
4.5. Relationship between O2 and other gases  
Disturbances in macro- and microcirculation either by primarily vascular origin or 
during secondary inflammatory disorders can profoundly alter the oxygenation profile of 
tissues. Many of the endogenous enzymes that utilize O2 are able to bind other gases as well, 
but often with lower affinity. The complex interplay of gaseous compounds is of particular 
importance in hypoxic pathologies, since in the lack of O2 new reactions can emerge, 
highlighting those processes which are usually in the background. A well-explored area of 
such interactions is that of O2 with NO (van Faassen et al. 2009). 
NO-linked effects in hypoxia 
NO production by the NOS isoforms is an O2-dependent mechanism. Under hypoxic 
and anoxic conditions NO can be formed from nitrite (NO2
−
) and from nitrate (NO3
 −
), with 
further reduction through NO2
−
. The main NO2
− 
 reductases in humans are as follows.  
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 XOR. The majority of Mo-containing enzymes are bacterial proteins (Hille 2013). There 
are four known Mo-containing enzymes in mammals and all four can act as NO2
−
 
reductase, namely XOR, sulfite oxidase, aldehyde oxidase and mitochondrial amidoxime 
reductase (Sparacino-Watkins et al., 2014; Maia et al., 2015; Wang et al., 2015). 
Especially in the intestine and in the liver, XOR has multiple roles during hypoxia and 
reoxygenation (ROS production by XOR during the reperfusion has been reviewed before 
in section 2.2), but a crucial catalytic activity of the enzyme is the reduction of NO2
−
 to 
NO. XOR is structurally similar to bacterial NO2
−
/NO3
−
 reductases (Zhang et al., 1998), 
and the NO2
 −
 reductase activity of XO is increases with acidosis and in hypoxic 
conditions (Hassoun et al., 1994; Kayyali et al., 2001).  
 Direct uncatalyzed reduction occurs at measurable rates in the stomach at low pH (and 
perhaps in ischemic tissues) (Lundberg et al., 1994).  
 Deoxygenated forms of Hb (and Mb) are allosterically regulated NO2
− 
reductases. Hb 
produces the NO with the highest rate at the half-loading point of O2 (about 35 µM) 
(Huang et al., 2005). The rate of NO2
− 
reduction is dependent on the O2 tension: with 
higher O2 concentrations more Hb is saturated and the number of available ferrous hemes 
for NO decreases. 
 Mitochondrial respiratory chain complexes III and IV can act as NO2
− 
reductases as 
well (Kozlov et al., 1999). Having a negative charge, NO2
− 
cannot diffuse freely into 
mitochondria, and only a fraction of cytoplasmic NO2
− 
is available intramitochondrially in 
the form of HNO2 (Samouilov et al., 2007). 
The NO formation from NO2
−
 under hypoxia is viewed as a salvage mechanism, as under 
such conditions physiological NO2
− 
concentrations are already sufficient to induce 
vasorelaxation (Dalsgaard et al., 2007). 
NO and reperfusion 
 NO2
−
-dependent cytoprotection was repeatedly shown in various IR models (Webb et al., 
2004; Duranski et al., 2005; Jung et al., 2006; Tripatara et al., 2007). NO is able to 
inhibit cell surface adhesion molecules both on endothelial cells and leukocytes, thereby 
preventing extravasation and the activation of PMNs (De Caterina et al., 1995). 
Furthermore, by the S-nitrosation of inflammatory transcription factors (e.g. activator 
protein-1 and NF-κB), NO exerts anti-inflammatory effects at the transcriptional level 
(Pilz et al., 1995). 
 S-nitrosation (one electron oxidation of a thiol group to form S-NO) of proteins and 
peptides leads to the formation of S-nitosothiols (RSNOs) (Stamler et al., 1992; Jia et al., 
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1996), a cGMP-independent signaling pathway of NO. The RSNOs formed are stable 
and can act as NO donor molecules. Reactive nitrogen species support the formation of 
RSNOs. On the other hand, in vitro evidence suggests that XO-derived O2
●−
 is able to 
decompose RSNO and lead to ONOO formation (Trujillo et al., 1998). 
 Peroxynitrite (ONOO) formation and the deleterious effects of NO are mostly 
connected. ONOO is an oxidant species formed in the diffusion-controlled reaction of 
NO with O2
●−
 (Beckman et al., 1990). XOR producing NO under hypoxia and O2
●−
 in the 
postischemic tissue may be an important source of ONOO (Godber et al., 2000). ONOO 
and ONOO-derived radicals (e.g. lipid hydroperoxides) can readily oxidize and/or nitrate 
biomolecules including tyrosine residues, thiols, DNA and unsaturated fatty-acid-
containing phospholipids. Irreversible tyrosine nitration at CI is a well known adverse 
effect of ONOO (Brown et al., 2004), whereas high ONOO concentrations lead to 
generalized protein and lipid modifications (Gadelha et al., 1997; Szabo et al., 2007). 
 
5. Mitochondrion: the hub of interactions of gaseous compounds 
While not much is known about the interactions between various gases in the 
eukaryotic cells, the importance of the topic is increasingly recognized. Protein complexes of 
the ETS are partially embedded in the IMM, exposing parts of them to the lipid bilayer and, 
therefore, to the apolar milieu. This is an important point to consider, since some of the most 
abundant gas mediators (e.g. NO) are far more soluble in lipids than in the aqueous phase. 
The mitochondrial ETS, particularly cytochrome c oxidase (CIV), is the target of the whole 
machinery of aerobe organisms which seek to at transport molecular O2. This enzyme 
catalyzes the reduction of O2 by ferrycytochrome to H2O; hence it is quite predictable that 
other gases can interact with it as well. Indeed, CO, NO, H2S and HCN all inhibit CIV 
(Cooper et al., 2008). More importantly, it has been shown that CIV inhibition by sodium 
azide leads to endogenous CH4 generation in plant cells and mammals (Wishkerman et al., 
2011; Tuboly et al., 2013b). Furthermore, it has been shown that CH4 inhalation improved 
mitochondrial OXPHOS in a partial hepatic IR model, at least indirectly (Strifler et al., 2016). 
If O2 levels are in the physiologic range, the affinity of NO for sGC is about 50 times 
higher than that for the cytochrome c oxidase (data from brain tissue at O2 levels of 30 µM 
(Brown et al., 1994)). However, with lower O2 concentrations this apparent gap decreases and 
NO inhibits CIV in competition with O2. 
Usually, the reduction of molecular O2 at CIV is not rate-limiting in mitochondrial 
respiration, but the partial inhibition of CIV by one gas will make it more rate limiting for 
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respiration, and in consequence more sensitive to other gases (Cooper et al., 2008). Quite 
significantly, hypoxia is an inhibitor of CIV as well. Therefore, under hypoxic conditions, the 
inhibitory effects exerted by other gases can be amplified. The KM of CIV is about 0.5 µM of 
O2, well below the O2 levels in the body; hence CIV is not rate-limited. (We should mention 
here that because of the physiologically low tissue O2 levels in the intestine, the mitochondria 
there might be prone to interactions with other gases). In contrast, if 60 nM of NO is present, 
KM of O2 rises to 30 µM, well above O2 levels in the intestine (Brown et al., 1994). In most 
cases, the reciprocal control of O2 and NO relieves inhibition. Under profound ischemia, 
however, vasodilation is ineffective and compensatory mechanisms fail to replenish O2 to 
mitochondria, resulting in gradually increasing NO concentrations.  
Under physiological conditions, when an excess capacity of OXPHOS is present, the 
partial inhibition of CIV by NO may operate in parallel with ATP production matching the 
needs of the cell, while providing a “regulated” ROS formation for signal transduction. The 
term “nitroxia” was suggested by Shiva and coworkers for a dysregulated state, having some 
of the characteristics of hypoxia, when excess NO substantially inhibits CIV, leading to ATP 
depletion despite sufficient O2 levels. In this case, enhanced ROS formation can be measured 
(Shiva et al., 2005).  
It is recognized that gaseous compounds are able to interact with other components of 
the mitochondrial electron transport machinery as well. The inhibition of CI by S-nitrosation 
is thought to be beneficial, protecting downstream complexes from pathologically increased 
ROS production under reperfusion (Brown et al., 2004; Shiva et al., 2009). Another 
mitochondrial target of gases is cytochrome c; CO, NO and H2S can also interact with this 
hemoprotein with different degrees of affinity. Notably, interactions of cytochrome c with 
cardiolipin, a component of the IMM, dramatically enhance the ligand interactions of 
cytochrome c, so gas interactions are far more likely (Kagan et al., 2005; Vlasova et al., 
2006).  
Interestingly, p66Shc, an alternatively spliced transcript from the SHC1 gene, can 
produce ROS acting as an oxidoreductase and can transfer electrons from mitochondrial 
cytochrome c to O2 (Giorgio et al., 2005). The role of mitochondrial p66Shc was postulated in 
the ROS-induced ROS release (Zorov et al., 2000; Galimov et al., 2014), ultimately leading to 
the induction of mitochondrial permeability transition. How the binding of gas molecules to 
cytochrome c influences this process has not yet been explored. 
Apart from reversible interactions of gases with mitochondrial enzymes, ONOO can 
inhibit CI, CII, CIV, ATP synthase, aconitase, Mn-SOD, creatine kinase, and probably many 
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other mitochondrial proteins in an uncontrolled manner (Cassina et al., 1996; Gadelha et al., 
1997). This obviously harmful consequence of pathologically elevated mtROS and NO levels 
can only be prevented by the timely inhibition of abnormal ROS and NO production. 
The interplay of CH4 with NO in mammals has not yet been investigated 
systematically. On the one hand, it was demonstrated that normoxic CH4 ventilation decreases 
tyrosine nitrosylation after an IR injury (Boros et al., 2012), a process which involves NO. On 
the other hand, it has been shown that the inhibition of CIV, an important target of NO under 
hypoxia, leads to CH4 generation (Wishkerman et al., 2011; Tuboly et al., 2013b). It should 
be added that the heme a3/CuB O2 reduction site of CIV is hydrophobic (Wikstrom, 2004), 
increasing the probability of interaction with gases that are more soluble in lipids than in the 
water phase. Moreover, some of the effects exerted by CH4 in model systems of inflammation 
can be explained by the indirect modulation of functions of NO. It is likely that the two gases 
are able to modulate the effect of each other at membrane interfaces, where their 
concentration is at its peak. The reaction of NO with O2 in hydrophobic membranes thought 
to be faster than in the aqueous phase. Based on model calculations, even with only 3% of 
lipids in the tissue volume, the majority of reactions of NO with O2 will occur within 
membranes (Liu et al., 1998). Taking into account the solubility of CH4, comparable changes 
can be estimated.  
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II. Aims 
1. Our first general aim was to explore the consequences and effects of normoxic CH4 
administration in a small animal model of IR-induced inflammation; the following specific 
goals have been addressed. 
- The first specific goal was to characterize the changes in epithelial and endothelial 
permeabilities induced by IR challenge in the rat small intestine. With this aim, we 
monitored the early and later biochemical consequences, the structural and 
hemodynamic changes in the intestinal mucosa; 
- The second goal was to detect specific biochemical markers of both oxidative and 
nitrosative stress to investigate the possible mechanism of action of exogenous CH4-
based treatments; 
- The third goal is based on our hypothesis that CH4 has direct influence on cell 
membrane rigidity. Therefore an additional goal was to investigate the influence of CH4 
on changes in erythrocyte deformability provoked by oxidative stress in vitro. 
2. Our second general aim was to better understand the mechanisms of CH4 action in models 
of tissue hypoxia with elevated ROS and RNS levels, with special emphasis on the possible 
relationship of CH4 with other biological gases, such as NO; the following specific goals have 
been addressed in this part of the study. 
- The first goal was to establish a bacterial endotoxin-based in vivo experimental model of 
inflammation to follow the changes in locally generated NO levels; 
- The second goal was to develop a specific and sensitive method to detect NO generation 
in the model established in the first goal; 
- The third goal was to examine the potential interplay of CH4 with NO directly 
investigating in vivo and ex vivo effects of CH4 administrations on the rates of NO 
generation in biological samples by means of electron paramagnetic resonance (EPR) 
spectroscopy technique and on-line chemiluminescence analyses. 
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III. Materials and methods 
1. An in vivo study to investigate the effects of CH4 treatments in mesenteric IR 
1.1. Animals 
The experiments were performed on 76 male Sprague-Dawley rats (280-320 g bw) in 
accordance with National Institutes of Health guidelines on the handling and care of 
experimental animals and EU Directive 2010/63 for the protection of animals used for 
scientific purposes, and it was approved by the National Scientific Ethical Committee on 
Animal Experimentation (National Competent Authority), with the license number 
V/148/2013. The animals were housed in plastic cages under 12/12 hr day-night cycle, 
standard air temperature and humidity conditions. All chemicals were obtained from Sigma-
Aldrich Inc. (Budapest, Hungary) unless otherwise stated. 
1.2. Surgical procedure and study design 
Rats fed on a normal laboratory diet with tap water ad libitum, were randomly allocated 
into one or other of the experimental groups. After overnight fasting, the animals were 
anaesthetized with sodium pentobarbital (50 mg/kg bw ip) and placed in a supine position on 
a heating pad. The trachea was dissected free and cannulated with a silicone tube, and the 
right jugular vein was cannulated with PE50 tubing for fluid administration and infusion of 
Ringer's lactate (10 mL/kg/h) during the experiments.  
The experiments were performed in two series (see Figure 1). In study 1 (the “early 
reperfusion” study), the animals were killed 60 min after the re-establishment of the 
mesenteric blood flow, while in the second set (the “late reperfusion” study), the reperfusion 
period and the corresponding control phase in the sham-operated animals lasted for 180 min. 
After a midline laparotomy, the superior mesenteric artery (SMA) was dissected free. 
Group 1 (n=6) served as a sham-operated control, while in Group 2 (IR, n=6) the SMA was 
occluded using an atraumatic vascular clip for 45 min. In CH4-treated Group 3 (IR+CH4, n=6) 
an artificial gas mixture containing 2.2% CH4, 21% O2 and 76.8% N2 (Linde Gas, Budapest, 
Hungary) was administered for 5 min before the end of the 45-min ischemia and for 10 min at 
the beginning of the reperfusion (Figure 1). In study 2 the protocol followed was identical, but 
the length of the observation and the reperfusion phase was different. 
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Figure 1. Experimental scheme  
 
1.3. Mucosal permeability measurements 
The epithelial permeability was determined with the 4 kDa fluorescein isothiocyanate-
dextran (FD4) method as described previously (Cuzzocrea et al., 1997). In short, a 5 cm long 
segment of the terminal ileum supplied by 3 blood vessel arcades was isolated at a distance of 
10 cm from the ileocecal valve. Silicone cannulas were placed and fixed into the oral and 
aboral ends of the segment and the lumen was gently flushed with 5 mL of 37°C saline and 5 
mL air, then the distal end was closed. Before performing measurements, the renal pedicles 
were ligated. Exactly at the moment of reperfusion (the “early reperfusion” study) or 120 min 
after (the “late reperfusion” study), the lumen was filled with 0.5 mL of warmed (37°C) FD4 
solution (25 mg/mL). Blood samples (0.3 mL) were then taken 5, 10, 20, 30 and 40 min later 
for plasma fluorescein concentration measurements with a fluorescence spectrophotometer (F-
2000 Hitachi, Japan, Ex: 492 nm; Em: 515 nm). The blood samples were stored on ice in the 
dark and centrifuged at 100g for 10 min. At the end of the experiment, the bowel segment was 
removed and weighed. The epithelial permeability index was expressed as a percentage of 
FD4 measured in the plasma and it was calculated using the formula [arterial FD4 
concentration (ng/mL) / luminal FD4 concentration (ng/mL)] *100. 
The vascular permeability index was determined using the azo dye Evans blue method 
as described previously (Szentpali et al., 2001). Stated briefly, 30 min before the end of the 
experiments 20 mg/mL/kg of Evans blue was given in iv bolus and 30 min later a blood 
sample was taken from the caval vein, together with a whole-thickness tissue sample from the 
ileum. The biopsy specimen was placed in 5 mL of formamide and homogenized for 1 min in 
a glass Potter homogenizer. The homogenate was incubated at room temperature for 20 h and 
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then centrifuged at 2500g for 30 min. The absorbance of the supernatant was determined at 
650 nm against a formamide blank with a UV-1601 spectrophotometer (Shimadzu, Japan). 
The concentration of Evans blue was determined from a standard curve and it was normalized 
to the protein content of the samples (Lowry et al., 1951). Similarly, blood samples were 
centrifuged at 600g at 4°C for 10 min and the absorbance of the 100-fold-diluted plasma was 
measured. The vascular permeability index was defined as the ratio of the tissue and plasma 
concentrations of Evans blue, i.e.[tissue Evans blue concentration / plasma Evans blue 
concentration] *100. 
1.4. Morphological analysis 
Histopathological analysis 
Full-thickness ileum biopsies were taken after 30 min of reperfusion in each group. 
The tissue was rinsed in ice-cold saline, fixed in 10 % buffered formalin, embedded in 
paraffin, cut into 4 µm-thick sections, and stained with hematoxylin and eosin. 
Photomicrographs were recorded with a 40x objective connected to a digital camera. 
In vivo histology 
The extent of superficial epithelial damage of the terminal ileum was evaluated by 
means of fluorescence confocal laser scanning endomicroscopy (CLSEM, Five1 Optiscan Pty. 
Ltd, Melbourne, Victoria, Australia) developed for in vivo histology. The mucosal surface of 
the terminal ileum 10 cm proximal to the cecum was exposed surgically and laid flat for 
examination. The injury of the mucosal architecture was examined after topical application of 
the fluorescent dye acriflavin. The surplus dye was washed off with saline, then the objective 
of the device was placed onto the mucosal surface of the ileum, and confocal imaging was 
performed 2 min after dye administration (1 scan per image, 1024 x 1024 pixels and 475 x 
475 mm per image). Non-overlapping fields were processed and evaluated by a modified 
semiquantitative scoring system (Érces et al., 2016). The grading was performed using five 
criteria: I. denudation of villi (0 = no denudation, 1 = at least one denuded area per field of 
view, 2 = more than one area without any recognizable villus structure per field of view; II. 
edema (0 = no edema, 1 = moderate epithelial swelling, 2 = severe edema); III. shedding (0 = 
a normal, clearly, well-defined villus structure without shedding cells, 1 = some shedding 
cells; fewer than 30 cells per field of view, 2 = shedding cells, more than 30 cells per field of 
view, 3 = severe debris); IV. epithelial gap (0 = no gap, 1 = less than 5 gaps per villi, 2 = 
more than 5 gaps per villi); V. longitudinal fissure on villi (0 = no fissure, 1 = presence of 
fissure). A blinded analysis of the same images was performed twice off-line. 
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1.5.  Hemodynamics 
The SMA flow signals (T206 Animal Research Flowmeter; Transonic Systems Inc, 
Ithaca, NY, USA) were measured continuously and recorded with a computerized data 
acquisition system (Experimetria Ltd, Budapest, Hungary). 
An intravital orthogonal polarization spectral imaging technique (Cytoscan A/R, 
Cytometrics, Philadelphia, PA, USA) was used for the visualization of the serosal 
microcirculation of the ileum. This technique uses reflected polarized light at the wavelength 
of the isosbestic point of oxyhemoglobin and deoxyhemoglobin (548 nm). Because 
polarization is preserved in reflection, only photons scattered from a depth of 200 mm 
contribute to image formation. A 10x objective was placed onto the serosal surface of the 
ileum, and microscopic images were recorded with an S-VHS video recorder (Panasonic AG-
TL 700, Matsushita Electric Ind. Co. Ltd, Osaka, Japan). The quantitative assessment of the 
microcirculatory parameters was performed off-line by a frame-to frame blinded analysis of 
the videotaped images. Changes in red blood cell (RBC) velocity (mm/s) in the postcapillary 
venules were determined in 3 separate fields by means of a computer-assisted image analysis 
system (IVM Pictron, Budapest, Hungary). All microcirculatory evaluations were performed 
by the same investigator. 
1.6. Biochemical measurements 
Ileum biopsies kept on ice were homogenized in a phosphate buffer (pH 7.4) containing 
Tris-HCl (50 mM, Reanal, Budapest, Hungary), EDTA (0.1 mM), dithiotreitol (0.5 mM), 
phenylmethylsulfonyl fluoride (1 mM), soybean trypsin inhibitor (10 μg/mL) and leupeptin 
(10 μg/mL). The homogenate was centrifuged at 4°C for 20 min at 24 000g (Amicon 
Centricon-100, Millipore Corporation, Bedford, Massachusetts, USA). Tissue nitrotyrosine 
(NTyr) concentration was determined in the supernatant, while myeloperoxidase (MPO) 
activity was measured in the pellet of the homogenate. 
Tissue myeloperoxidase (MPO) activity 
The activity of MPO as a marker of tissue leukocyte infiltration was measured in the 
pellet of the homogenate using the modified method of Kübler et al. (Kuebler et al., 1996). 
Stated briefly, the pellet was resuspended in K3PO4 buffer (0.05 M; pH 6.0) containing 0.5 % 
hexa-1,6-bis-decyltriethylammonium bromide. After three repeated freeze-thaw procedures, 
the material was centrifuged at 24 000g at 4°C for 20 min and the supernatant was used for 
MPO determination. Afterwards, 0.15 mL of 3,3’,5,5’-tetramethylbenzidine (dissolved in 
DMSO; 1.6 mM) and 0.75 mL of hydrogen peroxide (dissolved in K3PO4 buffer; 0.6 mM) 
were added to 0.1 mL of the sample. The reaction led to the hydrogen peroxide-dependent 
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oxidation of tetramethylbenzidine, which was detected spectrophotometrically at 450 nm 
(UV-1601 spectrophotometer; Shimadzu, Kyoto, Japan). MPO activities were measured at 
37°C; the reaction was stopped after 5 min by the addition of 0.2 mL of H2SO4 (2 M) and the 
resulting data were normalized to the protein content. 
Plasma ET-1 levels 
Blood samples (0.5 mL) were taken from the inferior caval vein and placed into chilled 
polypropylene tubes containing EDTA (1 mg/mL) at the end of the “late reperfusion” 
experiments (180 min after reperfusion), centrifuged at 1000g at 4°C for 30 min and then 
stored at -70°C until assay. The plasma ET-1 concentration was determined in duplicates by 
means of a commercially available enzyme-linked immunosorbent assay (ELISA) kit 
(Biochemica Hungaria Ltd., Budapest, Hungary) and expressed as fmol/mL. 
Intestinal O2
●−
 production 
The rate of O2
●−
 production in freshly minced intestinal biopsy samples was assessed by 
using the lucigenin-enhanced chemiluminescence assay described by Ferdinandy et al. 
(Ferdinandy et al., 2000) In short, approx. 10 mg of intestinal tissue was placed in 1 mL of 
Dulbecco’s solution (pH 7.4) containing 5 µM of lucigenin. The manipulations were 
performed without external light 2 min after dark adaptation. Chemiluminescence was 
measured at room temperature in a liquid scintillation counter by using a single active 
photomultiplier positioned in out-of-coincidence mode, in the presence or absence of the O2
●−
 
scavenger nitroblue tetrazolium (NBT; 20 µl). NBT-inhibited chemiluminescence was 
interpreted as an indicator of intestinal O2
●−
 generation. 
Tissue nitrotyrosine level 
Free NTyr, as a marker of ONOO generation, was measured by an enzyme-linked 
immunosorbent assay (Cayman Chemical; Ann Arbor, MI). Small intestinal tissue samples 
were homogenized and centrifuged at 15000g. The supernatants were collected and incubated 
overnight with anti-NTyr rabbit IgG and a NTyr acetylcholinesterase tracer in precoated 
(mouse anti-rabbit IgG) microplates, which were developed using Ellman’s reagent. The 
NTyr content was normalized to the protein content of the small intestinal homogenate and 
expressed in ng/mg. 
1.7. CH4 concentration measurement 
The CH4 concentration was measured by means of photoacoustic spectroscopy (PAS) 
(Tuboly et al., 2013a). PAS is a special type of spectroscopy that measures optical absorption 
indirectly via the conversion of absorbed light energy into acoustic waves. The amplitude of 
the generated sound is directly proportional to the concentration of the absorbing gas 
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component. The light source of the system is a near-infrared diode laser that emits around the 
CH4 absorption line at 1650.9 nm with an output power of 15 mW (NTT Electronics, Tokyo, 
Japan). The cross-sensitivity for common components of breath and ambient air were 
repeatedly examined, and no measurable instrument response was found for significant 
concentrations of CO2 or H2O vapour. The narrow line width of the diode laser provides high 
selectivity; the absorbance of CH4 is several orders of magnitude greater than that of H2O, 
CO2 or CO at 1.65 μm, the wavelength we used. The CH4 values were corrected for 
background levels and expressed in parts-per-million (ppm). 
The device was previously calibrated with various gas mixtures prepared by the dilution 
of 1 vol % of CH4 in synthetic air, and it has a dynamic range of 4 orders of magnitude; the 
minimum online detectable concentration of the sensor was found to be 0.25 ppm (3σ), with 
an integration time of 12 s (Tuboly et al. 2013). 
In a separate set of experiments, tissue CH4 concentration was measured multiple times 
in anesthetized rats after the inhalation of room air or artificial air containing 2.2% exogenous 
CH4. Immediately after 15 min of inhalation, a 200 mg ileum sample was taken, excess fluid 
was immediately wiped off and the tissue specimen was placed in a glass vial with 20 mL 
headspace volume and closed so as to be air tight. Parallel to taking ileum biopsies, 1 mL of 
blood was taken from the common carotid artery of the same animals through a silicone 
cannula and was subsequently transferred to identical glass vials. The outlet of the vials was 
connected to the pump of the spectroscope and headspace gas was pumped into the chamber 
of the device with a rate of 10 mL/min.  
2. In vitro and ex vivo studies for the detection of NO generation 
2.1. Animals 
The experiments were performed on male Sprague-Dawley rats (n=45; 250–300/390–
540 g bw; Animal Research Laboratories, Himberg, Austria/Charles River, Germany) which 
were kept under controlled standard animal housing conditions. The animals had free access 
to standard laboratory rodent food and water. They were kept for seven days prior to usage in 
experiments for accommodation. All interventions were conducted in compliance with the 
National Institutes of Health’s “Guide for the Care and Use of Laboratory Animals” with 
approval from the Animal Protocol Review Board of the city government of Vienna, Austria. 
All chemicals were obtained from Sigma-Aldrich (Vienna, Austria), unless otherwise stated. 
2.2. LPS treatment and study design 
LPS from Escherichia coli serotype 026:B6 (activity ≥500,000 EU/mg) was used for the 
dose dependence experiments. Six groups of rats were injected with various doses (0.2, 1.3, 
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2.5, 4.7, 6.3, and 8.5 mg/kg body weight) of LPS dissolved in saline (Fresenius Kabi, Bad 
Homburg vor der Höhe, Germany). Control animals were injected with saline only. Samples 
were then collected 16 h after the LPS injection. In a separate set of experiments, animals 
were divided into five groups. All rats were injected with the same dose of LPS (Escherichia 
coli serotype 026:B6, 8 mg/kg body weight, activity ≥10,000 EU/mg) dissolved in saline, and 
samples were taken 2, 4, 8, and 16 h after LPS treatment. Control animals were injected with 
saline only. The LPS solution was vortexed for 1 min and sonicated for 30 s before 
application, and subsequently injected in the penis vein under isoflurane anesthesia in a 
volume ranging from 0.5 to 0.75 mL. 
2.3. EPR spectroscopy 
EPR spectra were recorded at liquid nitrogen temperature (-196°C) with a Magnettech 
MiniScope MS 200 EPR spectrometer (Magnettech, Berlin, Germany) in a quartz finger-type 
Dewar flask filled with liquid nitrogen. The EPR spectra were then recorded at short- and 
long-scale ranges. The general settings for a short range were as follows: modulation 
frequency, 100 kHz; microwave frequency, 9.425 GHz; microwave power, 8.3 mW; 
modulation amplitude, 5 G; and gain, 200. NO–Hb complexes were recorded at 3300±200 G. 
The general settings for the long range care were as follows: modulation frequency, 100 kHz; 
microwave frequency, 9.429 GHz; microwave power, 30 mW; and modulation amplitude, 6 
G. Liver spectra were recorded at 3200±500 G. The spectra were quantified by the 
determination of magnitudes of different components of spectra and by double integration of 
EPR spectra.  
2.4. NO trapping  
Iron-bound NO in the intestinal tissue of rats with CH4 treatment was measured using 
the method described earlier (Kozlov et al., 2001b). Stated briefly, rats were injected 
subcutaneously with sodium diethyldithiocarbamate (Na-DETC; 500 mg/kg) and FeSO4 (50 
mg/kg, dissolved in 0.18 mM sodium citrate) separately with 5 minutes between the 
injections, 20 minutes before SMA occlusion. DETC forms a water-insoluble DETC-Fe 
complex with iron in the tissue compartment, which is able to bind and stabilize NO as a 
DETC-Fe-NO complex, and this permits the measurement of NO in the natural compartment 
where it was formed. 
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3. An in vitro microrheological study 
3.1. Study design, induction of oxidative stress and CH4 treatment 
 
 
 
Figure 2. Experimental protocol of the microhemorheological study 
 
Venous blood from healthy male volunteers was collected in lithium heparin coated 
tubes. Blood samples were placed into three groups, and incubated for 120 minutes at 37°C 
on a rollerbed before RBC aggregation and deformability measurements. A non-treated 
sample served as the negative control. Oxidative stress was induced with the addition of 
phenazine methosulfate (PMS, dissolved in phosphate buffered saline, final concentration 200 
µM) and an incubation for 120 minutes (Rabai et al., 2010). Before the study, a dose-response 
experiment was performed with PMS concentrations between 0 and 400 µM, to determine the 
effective concentration. In the third, CH4-treated group, the headspace of the sample was 
continuously perfused with a gas mixture containing 2.2 % CH4 in normoxic air (Messer 
Hungarogáz, Budapest, Hungary) for 10 minutes after at the end of the PMS incubation 
protocol. 
RBC deformability and the aggregation of samples were determined by means of 
ektacytometry and light-transmission aggregometry immediately after the incubation period. 
Samples were taken from the same vials for both measurements. 
3.2. RBC deformability 
RBC deformability in response to shear forces was determined via a LORCA 
ektacytometer (Laser-assisted Optical Rotational Cell Analyzer; R&R Mechatronics, Hoorn, 
Netherlands).  
Immediately after the treatment protocol, 20 µL of blood was suspended in 4 mL of a 
polyvinylpyrrolidon solution, with a viscosity of 29.8 mPas, and injected into the cylinder of 
the ektacytometer. During the measurement, the temperature was kept at 37°C. 
Deformation is characterized by the elongation index (EI) calculated from the diffraction 
pattern of laser light on elongated RBCs. The light was captured and analyzed by a video 
camera and a computer system that calculated an EI as the (length - width) / (length + width) 
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of the pattern for 9 different shear stress values ranging from 0.5 Pa to 50 Pa (Hardeman et 
al., 1994).  
3.3. RBC aggregation 
The aggregation characteristics of erythrocytes were assessed by using a light 
transmission method described earlier (Kiesewetter et al., 1982). Immediately after the 
treatment protocol, 30 µL of blood was transferred to a Myrenne MA-1 Aggregometer 
(Myrenne GmbH, Roetgen, Germany). 
The blood sample was first sheared at 600 s
-1
 to disperse all pre-existing aggregates, and 
then the shear rate decreased rapidly to low shear rates. The degree of aggregation was 
characterized by the aggregation index, which is calculated using the surface area below the 
light intensity curve in a 10 second period. Measurements were then performed at ambient 
room temperature. 
4. In vitro analysis of anoxic NO release 
4.1. Sample preparation 
Male Sprague-Dawley rats (350-450 g) were euthanized by decapitation under isoflurane 
anesthesia. The liver was excised and placed in ice-cold Ringer solution (B. Braun Melsungen 
AG, Germany), cut into small pieces, snap-frozen in liquid nitrogen and stored at -80°C until 
assay. After thawing, the tissue was weighted and supplemented in a 1:10 ratio with an 
incubation buffer containing 106 mM KCl, 5 mM KH2PO4, 20 mM Tris-HCl and 0.5 mM 
EDTA. The pH of the solution was set to 6.0 to mimic ischemic tissue with severe acidosis. 
Afterwards, the liver sample was homogenized with an overhead stirrer (RW16, IKA Werke, 
Germany). 
4.2. NO measurement protocol 
NO release from liver homogenate was measured on-line by means of chemiluminescence 
(Sievers 280i, General Electric, USA) under anoxic conditions, pH 6.0 and 37°C. 0.5 mL of 
diluted liver homogenate supplemented with 19 mL of incubation buffer and 38 µL antifoam 
was added into the glass chamber of the device. Then the samples were equilibrated with 
nitrogen or nitrogen containing 2.2% CH4 (Messer Hungarogáz, Budapest, Hungary) under 
continuous gas flow for 10 minutes. Afterwards, 4.4 mM NaNO2 was added and the NO 
released from the homogenate was measured in real-time for a 15 minute period.  
5. Statistical analysis 
For a statistical evaluation of the data, GraphPad Prism 5.01 for Windows (GraphPad 
Software, La Jolla, California, USA) was used. The statistical analysis was performed by a 
two-way analysis of variance of repeated measures followed by Bonferroni post-hoc test in 
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normally distributed data and Kruskal-Wallis one-way analysis of variance on ranks 
combined with Dunn’s method for pairwise multiple comparisons in groups showing a non-
Gaussian distribution. Pearson’s test was used to assess the statistical significance (p<0.0001) 
of correlations. Taking into account the fact that parts of the in vivo data were not normally 
distributed (not Gaussian), we displayed the data as box plots, where possible. Median values 
and 75
th
 and 25
th
 percentiles are given and in each case, p values < 0.05 were considered 
significant. 
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IV. Results 
1. The kinetics of CH4 transport 
The CH4 concentration in the baseline samples of non-CH4-producer animals remained 
below the background levels in the arterial blood and in the ileum tissue prior to the beginning 
of the experiment (figures 3A and 3B, “Baseline”). After 5 minutes of normoxic CH4 
inhalation with a flow rate of 300 mL/min, at the end of the SMA ischemia substantially 
increased CH4 concentrations were detected in the systemic arterial blood and there was a 
slight increase in the ileum as well (figures 3A and 3B, “Isch 45’ – CH4 5’”). 10 minutes into 
the reperfusion phase, at the end of the 15 min inhalation of normoxic CH4-air mixture, CH4 
concentration in the ileal tissue also increased (Figure 3B, “Rep 10’ – CH4 15’”). In samples 
taken at the 60
th
 minute of the reperfusion, 50 minutes after the end of CH4 treatment, no 
significant amounts of CH4 were found in intestinal or blood samples (figures 3A and 3B, 
“Rep 60’”). 
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Figure 3. CH4 transport to the intestine. CH4 concentrations in blood (A) and ileum (B) samples 
taken during the CH4-air inhalation protocol in a pilot study. An original recording of photoacoustic 
signals as a function of time. At the indicated time point during the experiments, a tissue sample of the 
ileum, weighing approximately 200 mg was taken and placed immediately in a glass vial. 
Simultaneously, blood samples (1 mL each) were taken from the common carotid artery into glass 
vials. Gas samples from the headspace (20 mL) were thereafter transferred to the photoacoustic 
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detection system and each tissue specimen was measured for 10 minutes. Values are expressed as 
parts-per-million (ppm) and are corrected for background CH4 levels. Baseline – prior to CH4 
inhalation and ischemia. Isch 45’ (CH4 5’) – end of mesenteric ischemia, 5 minutes of normoxic CH4 
inhalation. Rep 10’ (CH4 15’) – 10
th
 minute of reperfusion, end of the 15-min normoxic CH4 
inhalation. Rep 60’ – 60th minute of reperfusion. Empty vial - CH4 concentration without biological 
sample, used for background-correction. 
 
2. The small intestinal permeability 
Small intestinal epithelial barrier function 
The epithelial permeability (EP) index was determined to assess the barrier function of the 
intestinal mucosa during the re-establishment of the blood flow to the previously ischemic 
tissues (Figure 4A). The EP did not change in sham-operated, control animals, while the 
plasma levels of FD4 rose steeply in the IR group, which indicates a rapid loss of the 
epithelial barrier function. Normoxic CH4 treatment resulted in significantly lower EP levels, 
implying there were preserved interepithelial junctions. 
Later in the reperfusion (Figure 4B, below), the EP index in non-treated animals decreased, 
suggesting an improved barrier function as compared to that in the early phase; while in the 
CH4-treated group, the change was similar to those observed in the early phase of reperfusion. 
The EP index remained at the baseline level in the control animals. 
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Figure 4. Epithelial permeability. Changes in epithelial permeability (EP) in the sham-operated 
(empty circles), mesenteric IR (black squares), and CH4-treated IR (black triangles) groups during 
early (A) and late phases (B) of reperfusion. The EP was assessed in each period and the permeability 
index was calculated as described earlier (see the Methods section for a description of the 
experiments). The data are expressed as median, 25
th
 and 75
th
 percentiles. Here, ** means p<0.01 
between groups vs. sham-operated group; ### means p<0.001 between CH4-treated and IR groups, 
while ++ means p<0.01 and +++ means p<0.001 compared to baseline values within groups. 
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Small intestinal microvascular barrier function 
The vascular permeability (VP) assessed by Evans blue extravasation increased in the early 
reperfusion relative to sham-operated control animals, but statistically significant differences 
between the experimental groups were not detected either in the early (Figure 5A) or the later 
(Figure 5B) phases of reperfusion. 
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Figure 5. Vascular permeability. Changes in vascular permeability (VP) in the sham-operated 
(Sham, empty boxes), mesenteric IR (IR, checkered boxes), and CH4-treated IR (IR+CH4, hatched 
boxes) groups during early (A) and late phases (B) of reperfusion. The VP index was calculated using 
a spectrophotometric evaluation of Evans Blue extravasation (see Materials and methods). The results 
are expressed as median, 25
th
 and 75
th
 percentiles. 
 
Micro- and macrocirculatory changes 
Prior to the induction of SMA occlusion, the RBC velocity in the microvessels of the ileal 
serosa was similar in all groups (see Figure 6). In the 15
th
 min of reperfusion, the intestinal 
microcirculation of the IR group was significantly impaired. In the IR+CH4-treated groups the 
RBC velocity did not differ from the sham-operated groups, implying improved 
microcirculation. By the 120 min of the reperfusion, no differences could be seen among the 
groups. 
The SMA blood flow was assessed continuously during the experiments (Figure 7). In the IR 
and IR+CH4 groups, the complete cessation of blood flow was followed by different reactions 
during reperfusion. The SMA flow in IR group remained significantly low as compared to 
baseline levels; while in CH4-treated animals, the SMA flow was significantly higher 
compared to that in the IR group. 
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Figure 6. RBC velocity. Changes in red blood cell (RBC) velocity in the microvessels of the serosal 
surface of the ileum in response to a sham operation (empty boxes) or 45 min of mesenteric ischemia 
followed by 120 min of reperfusion (IR groups, checkered boxes) and in rats treated with a normoxic 
(21% O2) gas mixture containing 2.2% CH4 for 5 min at the end of the ischemia and for 10 min at the 
beginning of the reperfusion period (IR+CH4, hatched boxes). Measurements were performed at 
baseline conditions (Baseline), 15 min after reperfusion (Rep 15’) and 120 min after reperfusion (Rep 
120’). ** means p<0.01 between groups vs sham-operated group, ## means p<0.01 between IR vs 
IR+CH4 groups, + p<0.05 compared with baseline values within groups. 
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Figure 7. SMA blood flow. Changes in the superior mesenteric artery (SMA) blood flow in the sham-
operated (empty circles), mesenteric IR (black squares), and CH4-treated IR (black triangles) groups. 0 
min on the X axis denotes the start of reperfusion. Results are expressed as median, 25
th
 and 75
th
 
percentiles. Here, *** means p<0.001 between groups vs. sham-operated group; # indicates p<0.05 
between CH4-treated and IR groups, while +++ means p<0.001 compared with baseline values within 
groups. 
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ROS and RNS levels 
Tissue NTyr concentration (Figure 8A) is an indicator of protein nitration produced by a 
chemical reaction associated with ONOO generation. The NTyr levels were elevated by the 
180 min of reperfusion in the IR group as compared to those in the sham-operated controls, 
while the levels did not differ from the controls in the CH4-treated group. 
O2
●−
 levels 
A primary cellular ROS, O2
●−
, was detected in ileal biopsies at the beginning of experiments 
(Figure 8B), and no between-group differences were observed. At 15 min after the 
reestablishment of blood flow, the samples from the IR group contained significantly higher 
levels of O2
●−
 than those from the control and CH4-treated animals. 
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Figure 8. Intestinal nitrotyrosine levels and capacity to generate superoxide radical. Changes in 
mucosal NTyr (panel A) and O2
●−
 (panel B) production in sham-operated control animals (Sham, 
clear boxes) and after 45 min of SMA occlusion and 180 min reperfusion (IR group, checkered boxes). 
In the methane-treated group (IR+CH4, hatched boxes) the animals inhaled a normoxic (21% O2) gas 
mixture containing 2.2% CH4 for 5 minutes in the final phase of the ischemia and for 10 minutes in the 
initial phase of the reperfusion period (or 15 minutes in total). The NTyr level was measured by means 
of EIA from samples taken after 180 min of reperfusion and normalized to the total protein content of 
the tissue. O2
●−
 levels (panel B) were measured by chemiluminescence at the beginning of the 
experiment (Baseline), 15 min (Rep 15’) and 120 min after reperfusion (Rep 120’), and they were 
normalized to the protein content of the tissue sample. Data are expressed as median, 25
th
 and 75
th
 
percentiles. Here, ** means p<0.01 compared to the sham-operated group; ## means p<0.01 between 
the CH4-treated group and IR group, while +++ means p<0.001 compared to baseline values within 
groups. 
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Tissue ET-1 levels 
The ET-1 concentration was measured from plasma samples at the end of the 180-min 
reperfusion period. In the IR group, there was a significant elevation at 180 min after 
reperfusion relative to that in control animals. This elevation was significantly reduced in the 
IR+CH4-treated group (Figure 9A). 
 
Tissue MPO levels 
The activity of MPO, a marker enzyme of PMN granulocytes, was assessed in intestinal 
homogenates at the end of the late reperfusion phase. A significant MPO elevation was 
present in both the IR and the CH4-treated groups, indicating acute inflammation and 
extravasation of leukocytes into the tissue (Figure 9B). 
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Figure 9. Endothelin-1 and MPO. Changes in tissue myeloperoxidase (MPO) activity and the 
plasma endothelin-1 (ET-1) concentration at the end of the 180 min reperfusion in the sham-operated 
(Sham, clear box), IR (checkered box), and CH4-treated groups (IR+CH4, hatched boxes).
 
Here, * 
means p<0.05 between groups vs sham-operated group, # means p<0.05 between IR vs IR+CH4groups. 
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Structural integrity of small intestinal mucosa 
Tissue samples were taken in the early reperfusion phase for conventional histology to 
provide structural data on the ileum mucosa. In the sham-operated group (Figure 10A), villus 
morphology was normal, but in the IR group (Figure 10B) extensively damaged, denudated 
and progressively shrinking villi were typically found in association with increased luminal 
debris formation. Furthermore, the congestion of RBCs in the microvessels of the villi was 
seen. CH4 treatment (Figure 10C) preserved the integrity of the mucosal layer with moderate 
debris formation and slight alterations of the lamina propria. 
Intravital CLSEM images were recorded to get information on the structural condition of the 
surface of the epithelium and the microscopic histology data were evaluated using a 
semiquantitative scoring system (Figure 11D). Normal villi with intact epithelial cells were 
observed in the control group (Figure 11A). Relative to the typically continuous, unbroken 
epithelial lining in the sham-operated animals, the mucosa was severely damaged after a 30 
min reperfusion. Epithelial defects stretching across the villi were regularly seen (Figure 
11B). No epithelial disruptions on the lumen surface were present in the CH4-treated group 
(Figure 11C) and the microstructural damage (pathological changes?) reflected in the injury 
score was significantly lower than that observed in non-treated IR animals. 
 
 
Figure 10. Conventional histology. Representative photomicrographs of the ileum mucosa 30 
minutes after the end of the ischemia in sham operated animals (A), ischemia-reperfusion (B) and 
ischemia-reperfusion and CH4 treated group (C). The images were taken with a 40x objective after 
hematoxilin-eosin staining. 
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Figure 11. Confocal laser scanning endomicroscopic images of the intestinal epithelium. Top 
panel In vivo histology images recorded by confocal laser scanning endomicroscopy (CLSEM) after 
the topical administration of sodium acriflavine: A: Sham-operated group, B: IR group, 45 min of 
SMA occlusion and 30 min reperfusion, C: IR+CH4 treated group, 45 min of SMA ischemia and 30 
min reperfusion. Bottom panel Grading of in vivo histology on a semiquantitative scoring system. The 
plots show the median and the 25
th
 and 75
th
 percentiles. Here,
 
* means p<0.05 between groups vs. sham-
operated group, # means p<0.05 between IR vs IR+CH4 groups.  
 
3. The detection of NO by EPR without exogenously added spin-trapping molecules 
EPR spectroscopy was applied to validate measurements of NO levels using endogenous 
trapping molecules. 16 h after an LPS injection, there was a dose-dependent increase at g = 
2.075 and g = 2.042 in the complex EPR signal of liver, corresponding to hemoglobin-bound 
NO (NO–Hb) and Fe-bound NO (NO–Fe; Figure 12B). In blood samples taken from the 
same animals, only NO–Hb signals at g = 2.075 were present (Figure 12A). There was a 
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good correlation of increasing LPS doses with NO–Hb and NO–Fe signals (Figure 12C-E), 
which had been calibrated previously (data not shown). The correlation was strong between 
NO–Hb and NO–Fe signals as well (Figure 12F-H). 
 
Figure 12. Quantification of NO formed in cells and in blood upon LPS treatment and the 
characterization of NO pools. The dose of LPS varied from 0.2 to 7.3 mg/kg body weight. Blood (A) 
and liver (B) EPR spectra were recorded 16 h after an injection of 0.2 (S2, S7), 3.7 (S3, S8), 4.9 (S4, 
S9), and 8.5 (S5, S10) mg/kg body weight LPS or an equivalent volume of NaCl (S1, S6). NO–Hb in 
blood (C) and liver (D), and NO–Fe in liver tissue (E) as a function of LPS dose. The correlation 
between NO–Hb in blood and liver (F), NO–Fe in liver and NO–Hb in blood (G) and NO–Fe and NO–
Hb in liver (H). Abbreviations: m, slope; r, coefficient of determination; S, signal 
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4. The effects of CH4 on NO release under ischemia 
Using Na-DETC and exogenously added iron to form stable, intracellular NO–Fe–DETC 
complexes for EPR analysis, we measured NO levels in the duodenum and ileum of rats (see 
Figure 13). There was a trend showing increased NO concentrations at the end of a 45-min 
ischemia in both parts of the intestine as compared to those in sham-operated animals. The 
inhalation of a normoxic gas mixture containing 2.2% CH4 for 10 min resulted in lower levels 
of NO. During the reperfusion phase, we did not see any similar trends (data not shown). 
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Figure 13. NO-Fe-DETC levels in samples taken from the duodenum (panel A) and ileum (panel B) 
of rats during mesenteric IR with or without CH4 treatments. Control animals (Sham, empty bars), 
animals after 45 min of SMA occlusion without reperfusion (I group, checkered bars). In the CH4-
treated group (I+CH4, hatched bars), the animals inhaled a normoxic (21% O2) gas mixture containing 
2.2% CH4 for 10 min in the final phase of ischemia. Here, data are expressed as the mean ± SD (n=3 
each). Panel C: characteristic EPR signal of NO–Fe–DETC. 
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To estimate whether or not CH4 can modulate NO release from NO2
−
 in anoxic tissues, liver 
homogenate was incubated with pure N2 or N2 supplemented with 2.2% CH4. NO production 
was alleviated in the presence of CH4; reaching significantly lower levels as compared to 
those for the N2 only group from the 10
th
 min after adding NaNO2 (Figure 14).  
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Figure 14. The NO generation of liver homogenate under anoxia. After equilibration with N2 or N2 
containing 2.2% CH4, 4.4 mM NaNO2 was added (arrow). NO release was detected in real-time and it 
is plotted against the time elapsed. The signal intensity is proportional to the NO generated. Median 
values and the range are given. 
 
* means p<0.05 and ** means p<0.01 N2+CH4 vs N2 group (n=3 each). 
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5. The effects of CH4 on the microhemorheological parameters of whole blood 
The deformability of erythrocytes taken from human blood was measured using a laser-
assisted optical rotational method (Figure 15). Oxidative stress, induced by in vitro treatment 
with the oxidizer PMS, resulted in a significantly decreased elongation index from low to 
moderately high shear stress rates, as compared to that for the non-treated control samples. 
Normoxic CH4 incubation, applied after the oxidizer incubation, was able to partly counteract 
the decreased rigidity of RBCs at moderate levels of shear stress (Figure 15B-D). 
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Figure 15. RBC deformability. Deformability changes of RBCs in vitro under increasing shear stress 
rates (panel A) and values at 1.57 Pa (B), 2.81 Pa (C) and 5.00 Pa (D) depicted as box plots. The 
higher elongation indices represent more elongated, hence more oval erythrocytes. Control samples 
(black line and empty boxes), samples incubated with PMS for 2 hours to induce oxidative stress 
(PMS groups, grey line and checkered boxes) and blood samples treated with a normoxic (21% O2) 
gas mixture containing 2.2% CH4 for 10 min after 2 h of PMS challenge (PMS+CH4, dashed line and 
hatched boxes). On the shear-stress curve means ± SD are given, while the box plots show the median 
and the 25
th
 and 75
th
 percentiles. Here,
 
* means p<0.05 and ** means p<0.01 PMS vs sham-operated 
group and n = 4-5. 
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Oxidative stress in vitro increased the aggregation of erythrocytes at low shear-stress as 
compared to that in control samples (Figure 16). After applying CH4, these values 
significantly decreased to the level of non-treated control samples. 
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Figure 16. RBC aggregation. The light-transmission of rapidly aggregating samples at low shear 
rates was measured for 10 s and the aggregation index was calculated. Control samples (empty boxes), 
samples incubated with PMS for 2 hours to induce oxidative stress (PMS groups, checkered boxes) 
and blood samples treated with a normoxic (21% O2) gas mixture containing 2.2% CH4 for 10 min 
after 2 h of PMS challenge (PMS+CH4, hatched boxes). The plots show the median and the 25
th
 and 
75
th
 percentiles. Here, * means p<0.05 PMS vs sham-operated group and n = 4-5. 
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V. Discussion 
The main purpose of the thesis was to summarize and interpret previous data on the in 
vivo properties of exogenous CH4 in order to design and conduct further experiments, which 
help to extend our knowledge on the possible role and mechanisms of action of CH4 in 
mammalians. Today it is recognized that a variety of enzymes are generating gas mediators, 
molecules that exert important physiological functions. Also, there is a growing body of 
evidence which suggests that CH4 can be produced in the eukaryotic cell. The anti-
inflammatory potential of exogenously supplemented CH4 has been repeatedly confirmed as 
well, but it is still unclear whether endogenous CH4 levels are able to influence physiological 
or pathophysiological processes and important details of the mechanism of action still need to 
be clarified. In fact, there is an apparent difference between the amounts of CH4 produced 
endogenously and the concentrations used exogenously, which might raise concerns about the 
physiological relevance of CH4 as a gas messenger. From a pharmacological aspect, however, 
this is not a critical issue. Understanding the mechanism of action is the key to efficient and 
safe therapies, and on the basis of accumulated knowledge, the presumed physiological role of 
a compound can be clarified. In this work, the efficiency of a CH4-based therapy was 
investigated in a small animal model of oxido-reductive stress and in a second step of 
accompanying in vitro studies, we tried to delineate a feasible mechanism of action. We 
should note that the results still cannot fully explain the effectiveness of CH4, but they rather 
reflect the multifaceted responses of complex biological systems. 
1. The kinetics of CH4 transport in vivo 
In the case of NO or H2S, precursors stimulating endogenous release of the gas can be 
administered or enzymatic synthesis of the compounds can be induced (Szczesny et al., 2014; 
Gero et al., 2016). However, with CH4, direct delivery is the only feasible option. One 
approach to apply effective CH4 doses is by the enrichment of fluids, saline or other 
physiological solutions with the gas (Shen et al., 2016; Xin et al., 2016; Zhang et al., 2016). 
This delivery method is similar to H2-rich saline administration, which has been repeatedly 
used in vivo in animal models (Mao et al., 2009; Zheng et al., 2009; Chen et al., 2015). While 
giving the right dose may be easier, the storage of supersaturated CH4-containing solutions 
might be challenging problem. Another important issue is the relatively low solubility of CH4 
in aqueous solutions, and this limits the amount of CH4 which can be administered 
intravenously or intraperitoneally. Nevertheless, for chronic treatments it may be the method 
of choice, since CH4 can be given in repeated bolus doses. 
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In our studies, gas inhalation was used with artificial air containing 21% O2 and 2.2-
2.5% CH4. The solubility of CH4 is rather low in water, but much higher in the lipid phase, 
hence we hypothesized that inhalation provides a quick way of saturating tissues with CH4. 
The large alveolar surface of the lungs and the thin layer of alveolar cells with adjacent 
endothelium provide an ideal way to dissolve CH4 in the blood. Red blood cells contribute to 
40-50% of the total volume of the circulating blood; therefore erythrocyte lipid membranes 
are good candidates to carry the gas. Also, it has been shown that in this concentration range, 
CH4 in the inhaled air has no measurable impact on O2 delivery and saturation (Boros et al., 
2012). 
Despite the fact that the efficacy of CH4 after inhalation has already been 
demonstrated in different animal models of diseases, the distribution of the molecule has yet 
to be determined. With this in mind, we sought to assess the kinetics of tissue and blood levels 
of CH4 during and after the inhalation protocol was used in vivo (see figures 3A and 3B). We 
found that even a brief inhalation of CH4 resulted in high amounts of gas being dissolved and 
transported by the blood. Due to the apolar property of the molecule, the majority of gas is 
transported by RBCs (and lipoproteins) and was reasonable to suppose that the dissolved CH4 
influences properties of the RBC membrane. Upon reperfusion, the CH4 content of the 
systemic blood immediately starts to equilibrate with the CH4 level in the previously ischemic 
tissue, reducing the time needed to reach the target cells. 
In parallel with blood CH4 measurements, levels of the gas in the intestinal tissue were 
also assessed. There was a slight increase in CH4 levels during ischemia as a consequence of 
the omnidirectional diffusion of the gas. Due to its non-polar properties, CH4 can reach tissues 
without perfusion; hence it can exert effects under deep hypoxia. Upon reperfusion, as the 
blood flow restarted in the tissue, the levels of the gas rose significantly. Thereafter, about 50 
min after the end of normoxic CH4 inhalation no CH4 is measurable either in blood or in the 
intestine. One limitation is that direct measurement of the actual levels of CH4 dissolved in 
the tissue is not possible using the methods described here. In our study the headspace gas 
concentrations were measured over 10 min, during which the previously dissolved blood or 
tissue CH4 continuously equilibrated between the samples and the gas phase. During 
inhalation, the intracellular levels are definitely higher than the amounts measured.  
2. The bioactivity of exogenous CH4 in the intestine 
Enterocytes are energetically very active, and there is a delicate steady-state of cell 
loss and re-epithelialization in the small intestine. The maintenance of physical and 
immunological barriers between the interior milieu and intestinal lumen is of vital importance, 
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but the intestine is sensitive to hypoxia and the GI system is among the most vulnerable 
organs during circulatory redistributions (Vajda et al., 2004). Although small fluctuations of 
metabolites can be compensated by high-energy phosphate systems within the cells of the 
bowel (Kitzenberg et al., 2016), longer periods of ischemia or ischemia followed by a rapid 
reestablishment of the blood flow leads to severe damage. 
The anti-inflammatory properties of CH4 have already been examined in intestinal IR 
(Boros et al., 2012) and we sought to look at the function of mucosal barrier in this setting. 
Here we could show that even a brief, 15-min normoxic CH4 treatment modulated epithelial 
component of transmucosal permeability significantly and effectively prevented the IR-
induced barrier loss in the early reperfusion phase (see figures 4A and 4B). The rationale 
behind the timing and dosage of CH4 treatment was provided by the previous reports.  
The assessment of the lumen-to-plasma clearance of the 4 kDa MW FITC-labelled 
dextrane allowed us to determine paracellular permeability, mediated predominantly by TJs 
(Szabo et al., 2006). TJs are membrane-bound protein complexes connected to the 
cytoskeleton (Laukoetter et al., 2006). The maintenance of the closed conformation is energy 
dependent; therefore deteriorating intracellular ATP levels increase permeability 
(Wattanasirichaigoon et al., 1999). CH4 can in theory protect TJs from opening by directly 
influencing membrane fluidity or by preserving the ATP levels of epithelial cells; moreover, it 
can act indirectly, such as by a NO-mediated mechanism. Actually, the reduction of tissue 
NTyr levels does indeed suggest that CH4 may improve the epithelial barrier function by 
limiting the inhibitory effect of NO on mitochondrial electron transport chain complexes I and 
IV (Brown, 2001). This, in turn, may elevate ATP production early in the reperfusion phase, 
allowing cells to attain sufficiently high energy levels to maintain TJ proteins in the tightly 
closed conformation. 
In parallel with the improved barrier function, both conventional histology and 
CLSEM revealed preserved structure of the most luminal layers of the mucosa (see figures 10 
and 11). There is a multitude of factors contributing to mucosal injury upon reperfusion 
(Granger et al., 2015). In the current protocol the decrease in epithelial permeability after CH4 
inhalation was associated with reduced ROS and RNS generation and decreased ET-1 levels. 
In addition the CH4 treatment influenced the PMN infiltration, a specific cellular component 
of inflammatory reactions (figures 8 and 9). CH4 treatment improved both serosal 
microcirculation and the SMA flow facilitating oxygen delivery to cells and allowing 
effective oxidative phosphorlylation in mitochondria (see figures 6 and 7). The normalized 
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ET-1 plasma levels in the CH4-treated groups may reflect the improved local microcirculatory 
state on one hand and reduced inflammatory activation on the other hand.  
There are, however, other links between the improved functional and structural status 
of the GI mucosa upon CH4-treatment. It was shown previously that normoxic CH4 treatment 
modulated XOR-derived O2
●−
 (Boros et al., 2012). However, extracellular, XOR-derived O2
●−
 
can activate PMNs through the TLR4 - NF-κB pathway (Lorne et al., 2008). The significantly 
reduced ROS and RNS levels (O2
●−
 and NTyr) after CH4 treatment can further prevent 
overwhelmed PMN activation and, as a consequence, the consumption of O2 by NADPH 
oxidase. Since one of the main determinants of mucosal microcirculation during reperfusion is 
an enhancement of the interactions between leukocytes and the endothelium (Vollmar et al., 
2011), a reduced number of activated PMNs can readily improve tissue perfusion. 
Early barrier dysfunction is a crucial in the development of delayed and remote organ 
injury following mesenteric IR. Postischemic gut serves as an incubator, where endotoxin 
leaking from the lumen to the interstitium primes PMNs (Moore et al., 1994). Significantly, 
the direct effect of normoxic CH4 on NADPH oxidase activation was shown earlier (Boros 
2012, Mészáros, unpublished data). This observation is in agreement with the findings 
presented in a recent publication of Zhang and coworkers, who provided conclusive evidence 
that CH4-enriched saline solution suppresses TLR4-induced nuclear factor-kappa B (NF-κB) / 
mitogen-activated kinase (MAPK) activation in cultured macrophages.  
The study design allowed us to determine the barrier function immediately after 
reperfusion and in the later phases, the effects of CH4 inhalation were also studied 60 min and 
180 min after the restoration of the mesenteric blood flow. The epithelial barrier of the ileum 
was already partially restored in the later phase of the reperfusion, as indicated by the lower 
FD4 clearances (see Figure 4.). In fact, the restoration of the epithelial barrier is a remarkably 
speedy process, involving the flattening of epithelial cells to cover injured villus surface and 
the shrinkage of the villi to reduce the damaged area (Derikx et al., 2008; Matthijsen et al., 
2009; Grootjans et al., 2011). Improved micro- and macrocirculation, restored O2 supply and 
the normalization of the energetic state of the intestinal cells can all contribute to the efficacy 
of this process, leading to the closure of TJs. However, the difference between the intensities 
of early and later changes in epithelial permeability suggest that upon re-establishment of the 
blood and oxygen supply, the endogenous defense mechanisms cannot immediately control or 
counteract the damaging reactions. Salvage therapies should target the initial steps to avoid 
long-term or distant consequences of the barrier damage, and CH4 treatment can fill this need. 
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Even a brief 15-min CH4 inhalation preserved the function of the postischemic gut, hence 
continuous or longer CH4 supplementation might have additional beneficial effects.  
The effects of CH4 on the IR-induced changes in vascular permeability are less clear 
because in this model the epithelial and endothelial permeability-specific changes were 
affected differentially by the IR cycle. Epithelial permeability significantly deteriorated 
immediately after reperfusion, while the extravasation of the circulating endothelial tracer did 
not increase to a great extent. Hence, the relative effect of CH4 administration on 
microvascular permeability could not been evaluated simultaneously. Nevertheless, possible 
technical limitations (i.e. interaction between FITC-labeled dextrane and Evans blue 
measurements) cannot be ruled out. The epithelial and endothelial permeability measurements 
were conducted simultaneously in the same animal for technical and ethical reasons, and this 
approach could influence the sensitivity of these methods. Therefore, future studies are 
needed to examine the influence of CH4 on microvascular permeability directly and 
separately. 
3. The detection of NO in biological samples 
Along the above lines, one might suppose that CH4 accumulates transiently at 
membrane interfaces, and a disproportionate increase in relationship with other gases, such as 
NO, may alter enzyme-linked processes, and ultimately mitochondrial function. Although 
much is known about the role of NO in physiology and pathophysiology, the determination of 
its actual levels in biological samples is not an easy task. NO has a half-life of milliseconds in 
tissues, much shorter than other inflammatory mediators. The determination of NO2
−
/NO3
−
 
amounts by the Griess reaction or with chemiluminescence methods with higher sensitivity is 
an option, but in hypoxia, when nitrite reductases consume NO2
−
, these can lead to erroneous 
results (Griendling et al., 2016). EPR spectroscopy is currently the most suitable method used 
to measure NO directly. It has very high specificity for NO as it forms complexes with 
exogenously added spin traps (e.g. Na–DETC and FeSO4). Unfortunately, these compounds 
are toxic. Moreover, such molecules can interfere with endogenous NO utilizing pathways 
through their high affinity to NO. 
An alternative is to utilize endogenous traps of NO for this purpose. Intracellularly 
produced NO reacts with ferrous ions to form dinitrosyl–iron complexes (NO–Fe) (Sergent et 
al., 2005). In contrast, in the vasculature NO forms mononitrosyl–hemoglobin complexes 
(NO–Hb) (Gow et al., 1998) with hemoglobin. Since no ferrous ions occur in the blood, the 
two complexes, located at g = 2.075 and g = 2.042 are characteristic for NO–Hb and NO–Fe, 
respectively. 
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LPS administration is a standard way of inducing acute TLR4 - NF-κB-mediated 
inflammation. We were able to demonstrate in intact, non processed, frozen samples that LPS 
increased hepatic NO levels in a dose-dependent way, both in the intracellular and 
intravascular compartments and NO–Hb levels in the systemic circulation (see Figure 12). 
The concentrations of NO in naturally occurring complexes were substantially lower 
compared with previous values stated in the literature of intracellular NO using the specific 
NO trap iron-diethylthiocarbamate in a similar model (Kozlov et al., 2005). We may conclude 
that only part of NO produced intracellularly is scavenged by dinitrosyl–iron complexes and 
the residual NO contributes to physiological NO signaling or diffuses in the blood (Kozlov et 
al., 2001a).  
 
Figure 17. Endogenous traps of NO inside parenchymal cells and small blood vasculature of the 
liver. This scheme shows that NO–Hb complexes predominantly reflect extracellular NO generation 
by immune cells, whereas NO–Fe is a matter of intracellular NO synthesis. After being synthesized by 
hepatocytes, NO is trapped by ferrous ions (Fe
2+
) from the cytosolic free iron pool, which forms a 
dinitrosyl–iron complex (NO–Fe) with two NO molecules and two thiol groups of proteins (SH). We 
assume that a small fraction of the NO molecules synthesized in hepatocytes diffuses into the 
microvasculature, where together with the NO molecules synthesized by immune cells (granulocytes, 
Kupffer cells), it forms mononitrosyl–hemoglobin complexes (NO–Hb).  
 
4. The interaction of CH4 with NO-related nitrosative stress 
NO is an exemplary double edged sword in biology. In nanomolar concentrations it is 
vasorelaxant and antiadhesive, but in the micromolar range NO inhibits mitochondrial 
respiration in a reversible way (Cooper et al., 2007; Cooper et al., 2008). It is unlikely that 
NO can inhibit cytochrome c oxidase during normoxia due to the high KM of the enzyme for 
NO. But under hypoxia and with high NO concentrations it is a possible pathway. In parallel, 
the half-life of NO is substantially longer if O2 levels are low (Thomas et al., 2001). In fact, 
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elevated NO levels could be present during the ischemic phase, as data obtained by means of 
EPR indicates. With CH4 treatment, however, the overproduction of NO could be reduced 
(see Figure 13). Significantly, we detected NTyr formation in the intestinal tissue, an indicator 
of ONOO, which requires both O2
●−
 and NO to form. The non-specific nitration of ETS 
proteins by ONOO is an additional, non-reversible inhibition of mitochondrial OXPHOS 
(Brown et al., 2004). Thus, the reduction of NTyr levels after CH4 treatment is an indirect 
sign of the influence of mitochondrial and NO-linked reactions. 
The source of NO under hypoxia is thought to be NO2
–
, reduced mostly by enzymatic 
reactions and by small molecules under acidic pH. Apart from hemoglobin within RBCs and 
the mitochondrial ETC itself XO acts as NO2
–
 reductase as well. It has been shown that CH4 
inhibits XOR under normoxic conditions, a feature which has important role in alleviating 
ROS-induced damage during reperfusion, when XO is one of the main ROS generating 
enzymes. The same enzyme can function as NO2
–
 reductase under hypoxia and low pH, 
conditions, which are fulfilled during ischemia. 
Considering this information, we set out to measure NO release in real-time in vitro 
from liver tissue homogenate under anoxic conditions, mimicking ischemic tissue. After 
addition of Na-NO2
–
 as a source of NO, in the anoxic-CH4-incubated group, the production 
rate of NO was significantly lower than that with N2 atmosphere only (see Figure 14). 
Endogenous levels of XDH are similarly high in the liver and in the small intestine. 
Accordingly, it can be assumed that modulation of XO by CH4 contributes to the reduced NO 
levels, but other mechanisms cannot be excluded with certainty. How exactly CH4 regulates 
NO levels is still unclear, but the interaction of the molecule with any of the O2-dependent 
NOS isoforms seems unlikely, considering the deep hypoxia during ischemia. Nevertheless, 
modulation of iNOS induction during the reperfusion cannot be ruled out. 
Taken together, we were able to demonstrate that increased CH4 input reduces NO 
production and NTyr levels in hypoxic organs and in tissue homogenates under anoxia. 
Apparently, there is a contradiction between the reduction of anoxic/hypoxic NO generation 
and improved microcirculation upon reperfusion. Nevertheless, the maximal vasodilating 
effect of NO requires much lower levels than those needed for inhibition of cytochrome c 
oxidase. What is more, it was demonstrated previously that intracellular NO readily diffuses 
out from the cells in the circulation, but intravascular NO does not diffuse into the cells 
(Kozlov et al., 2001a). Spatial differences of NO production and utilization thus play a 
substantial role, but the explanation of this phenomenon requires more study. 
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5. The direct action of CH4 on erythrocyte deformability 
The tissue NTyr level is an indicator of protein nitration, associated with elevated 
ONOO levels. ONOO is a potent initiator of membrane lipid peroxidation (Hogg et al., 1999) 
and it was reported earlier that IR-associated lipid peroxidation decreases membrane fluidity 
in various tissues (Dobretsov et al., 1977) and in erythrocytes as well (Watanabe et al., 1990). 
RBCs are rich in iron, which catalyzes ROS formation through the Fenton-reaction, making 
them highly susceptible to IR damage (McCord, 1985; Baskurt et al., 1998; Nanobashvili et 
al., 2002). The membrane and cytoskeleton are together responsible for altering the shape of 
erythrocytes (Reinhart, 2001). Lipid peroxidation breaks the connection between the two 
components (Mohandas et al., 1993) and, consequently, both deformability and aggregation 
of the RBCs is influenced in a detrimental way (Kayar et al., 2001). Brath et al. reported 
worsened RBC deformability and increased aggregation in the early reperfusion after 
experimental mesenteric ischemia in the rat portal vein (Brath et al., 2010). Normal 
erythrocytes are approximately 25% larger than the mean diameter of capillaries, so RBC 
deformability is a prerequisite in normal capillary blood flow (Reinhart et al., 1985; Baskurt 
et al., 2003). 
Based on this background, we evaluated RBC velocity as a measure of perfusion in the 
serosal microvessels, and direct intravital data were obtained on the deranged intestinal 
microcirculation. Furthermore, CH4 inhalation was associated with improved serosal 
microcirculation and the treatment also influenced the SMA flow. Hence, we hypothesized 
that CH4 can modulate erythrocyte deformability upon being dissolved in the membrane and it 
may restore the bullet-shaped RBCs and allow them to flow freely through microvessels, thus 
improving microcirculation. With this in mind, an in vitro microrheological study with human 
whole blood was designed without the confounding in vivo effects of vasoactive metabolites. 
From methodological considerations, PMS, an oxidizing agent was used prior to normoxic 
CH4 treatments, an approach analogous to in vivo CH4 application during the reperfusion 
phase only. We demonstrated that PMS incubation significantly reduced the elongation index 
of RBCs, thereby confirming the contribution of lipid peroxidation in this model system (see 
Figure 15). Upon normoxic CH4 treatment, the RBC deformability improved at low-to-
moderate shear stress rates, suggesting a direct effect of CH4 on membrane fluidity and/or 
membrane-cytoskeleton junctions. 
Some studies claim that pathological RBC aggregation plays an even greater role in 
microcirculatory dysfunctions. Therefore, aggregation was measured in the same 
experimental setting at low shear stress rates. Once again, the increased aggregation index of 
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RBCs provided evidence for the role of oxidative stress in our set-up; and CH4 treatment 
alleviated this response (see Figure 16). Moreover, with higher PMS concentrations, the effect 
of CH4 treatment was even more pronounced (data not shown). Thus, these data provide 
evidence for the direct effects of CH4 exerted in biomembranes of erythrocytes. Interestingly, 
XO inhibition with allopurinol prevents the RBC rigidity changes after IR in vivo (Nemeth et 
al., 2006). Since CH4 is able to inhibit XO (Boros et al., 2012), an improvement of the 
microcirculation upon CH4 treatment is the net result of a complex mechanism, inhibition of 
XO leads to a decreased O2
●−
 production and less membrane damage, while, at the same time, 
the accumulation of CH4 in the lipid phase further increases RBC deformability. 
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VI. Summary of the new findings 
Previous reports with exogenously administered CH4 corroborated the findings on the anti-
inflammatory effects of the molecule, showing alleviated TNF-, IL-6, IL-1β levels, 
improved antioxidative defense mechanisms and reduced signs of oxidative damage. Based 
on these results two hypotheses for the mechanism of action were formulated and tested.  
 
1. CH4 is quickly transported from the lungs to the small intestine by the circulating blood. 
After the inhalation of normoxic air containing 2.2% CH4 blood concentration of CH4 
increases at least 2-3-fold over its basal levels; this increase is sufficient to modulate the 
generation of ROS and RNS. 
2. The early and later consequences of intestinal IR were characterized by biochemical, 
macro- and microcirculatory and morphological parameters. The IR-induced circulatory 
and structural damage was accompanied by increased epithelial permeability, 
demonstrating mucosal barrier damage. Normoxic CH4 inhalation effectively prevented 
the elevation of intestinal epithelial permeability, maintaining structural integrity of the 
mucosa and improving biochemical signs of inflammation in the early reperfusion. These 
data support previous findings on CH4 bioactivity and establish a mucosa-protective role 
for exogenous CH4 to modulate the IR-induced pro-inflammatory activity locally in the 
small intestine. 
3. A new, toxic spin trap-free EPR spectroscopy method was developed for NO detection. 
The method was validated for NO measurements from both the intra- and extracellular 
compartments of the same samples in tissue biopsies.  
4. With EPR spectroscopy reduced NO levels were detected in the intestinal tissue after 
normoxic CH4 administration, and this finding was supported by in vitro data collected in 
anoxic liver tissue during CH4 incubation. Collectively, these results confirm that 
exogenous CH4 administration effectively reduces NO levels in the ischemic tissue. 
5. The results of this study revealed that CH4 in vitro improves the deformability of red 
blood cells during simulated oxidative stress, which may contribute to the improvement 
of the effectiveness of mesenteric microcirculation in the postischemic small intestine. 
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